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6ABSTRACT
Copy number variation (CNV) has been acknowledged as an important
contributor to variation in the human genome, and copy-variable regions
harbouring genes are interesting subjects of research for their potential
phenotypic effects. However, despite the extensive and continuing discovery
of CNVs, multiallelic loci remain technically challenging to measure and study.
In this thesis, a PCR-based measurement system for the tandemly repeated
CNV that harbours the DEFA1A3 locus has been developed. This locus can
either have the DEFA1 or the DEFA3 gene in any given copy of the repeat; the
two genes differ by a single nucleotide difference in the coding sequence. This
CNV has previously been shown to vary from 4 to 11 copies in a sample of the
UK population. The use of this measuring system has allowed a usefully
accurate measure and some characterization of this CNV in Europeans, Asians
(Chinese and Japanese) and African (Ibadan, Nigeria) samples from the
HapMap project, agreeing with the previously found copy number range in
Europeans and showing more variability in non-Europeans. Typing of three-
generation CEPH families has allowed the inference of haplotype copy
numbers from segregation analysis. Combining haplotype data for some CEPH
HapMap samples that were part of these families with their SNP genotypes in
the same LD block has shown copy number lineages that are surprisingly well-
tagged by SNPs. SNP rs4300027 allows the division of copy number
haplotypes into low (2 and 3-copy) and high (4 and 5-copy) groups in
European HapMap samples, a result that has been corroborated in an
independent set of European samples. The Asian and African HapMap
samples have failed to show this particular association. However, Japanese
samples show copy number lineages tagged by other SNPs, an association not
observed in other populations. In the second part of the study, an attempt has
been made to explore the phenotypic effects of this variable locus. Copy
number-tagging SNPs have been used to investigate published GWAS for
indirect signals of association with DEFA1A3 copy number. Preliminary
experiments for studying protein expression levels of DEFA1 and DEFA3 have
been carried out and the possible role of this CNV as a modifier locus in Cystic
Fibrosis disease severity has been investigated through direct typing of CF
samples with clinical data, and indirectly through interrogating a CF GWAS.
71. INTRODUCTION
1.1. Copy Number Variation in the Human
Genome
Human Genomes Vary
The human genome is a dynamic entity. In a diploid cell, the nuclear genome
is about 6 billion base pairs, packaged with the help of proteins into 23 pairs
of chromosomes. It is subject to changes in its sequence and structure by cell
processes, mainly replication of the genome prior to cell division and by
extrinsic factors including chemical, physical and biological agents that are
collectively labelled as mutagens. Most changes are thought to occur during
replication. Although replication of the genome is a high-fidelity process, it is
not always perfectly accurate and can result in errors. These errors can be of
various kinds, but the mutation rate for the most common variation, single
base substitution, is on average 3x10
-8
mutations/nucleotide/generation (Xue
et al., 2009). Many changes in genes are not compatible with life, and thus
most changes observed in human genomes are in the non-coding sequences
and relatively few in the genes. However, because of obvious phenotypic
changes, e.g. disease states, brought on by mutations in or around genes,
these are disproportionately studied. Changes in genes may affect function by
causing a decrease or complete loss, or may result in giving rise to new
functional alleles or duplicated genes, or may not alter function. The sum of
all the changes that have accumulated in the human genome, or were already
present in the ancestors of humans, and are now observed in present day
humans through various DNA technologies, is referred to as human genome
variation. The most prevalent form of genomic variation is the change of
single nucleotides, Single Nucleotide Polymorphisms (SNPs). About one SNP
per 300 bp is observed. VNTRs (variable number of tandem repeats) like mini-
and microsatellites, are less frequent with one per few kilobases, but are
highly polymorphic with several kinds of alleles for any given locus. Small
insertion/deletions (indels) are also about as frequent as microsatellites, but
like the majority of SNPs, only biallelic. The most recently appreciated kind of
genomic variation is structural variation, of which copy number variation is
the most common.
8Copy Number Variation
Variation in copy number of human genomic segments containing genes has
been observed for several decades. Genetic analyses of thalassaemia patients
showed the deletion of alpha globin genes which are present in four copies in
the general population instead of two copies per diploid genome. Similarly,
the genetic analysis of Rh-negative versus Rh-positive individuals showed that
the Rh-negative phenotype results from deletion of both copies of the RHD
gene (Colin et al., 1991). Such few examples of gene deletions/duplications
which affected single-gene phenotypes and large, microscopically visible
structural genomic changes were known before the era of human genome
sequencing. With the availability of a reference human genome sequence (de
Jong et al., 2001) and subsequent development of genomic hybridization and
SNP arrays, the last decade saw the discovery of the widespread copy number
variation in the human genome (Iafrate et al., 2004, Sebat et al., 2004). Copy
number variation is a kind of structural variation defined as the deletion or
duplication of 1 kb or larger DNA segments such that they can be present in
varying number of copies in contrast to the usual two copies for most of the
genome in a diploid cell. Such variable DNA segments are usually referred to
as copy number variants (CNVs), but can also be called copy number
polymorphisms (CNPs) in the literature (Redon et al., 2006). While these two
terms are often used interchangeably, sometimes they are used to
differentiate between rare and common variants, as by McCarroll et al
(McCarroll et al., 2007). Because of their size, these structural variations are
thought to involve more DNA bases in variation between any two human
genomes than SNPs (Redon et al., 2006).
One way of classifying CNVs is on the basis of their origin and complexity:
simple CNVs, which are usually biallelic and characterized by a single event of
deletion or duplication such that all existing haplotypes are descendants of
the original variant, and multiallelic or complex CNVs, which due to recurrent
changes have several haplotypic structures, such that the same copy-number
haplotype could have arisen more than once (Figure 1.1). This means that
simple CNVs are generally found on the same haplotypic background on which
they arose which allows their genotypes to be inferred indirectly by
genotyping SNPs in LD with them (Hinds et al., 2006). On the other hand,
complex CNVs have undergone several rounds of copy number changes
resulting in a complex spectrum of haplotypes in the population. Of course, a
simple CNV could in due time become more complex with the addition of new
haplotypes due to further structural changes, and all complex CNVs were at
some point during their evolutionary history a simple duplication.
9Figure 1.1 A cartoon showing examples of simple and complex CNVs
So far CNVs have most commonly been discovered and studied using DNA
array hybridization methods, where the loss or gain of DNA in one genome
with respect to another is observable. Earlier arrays had DNA probes several
kilobases long which allowed only a relatively rough estimation of CNV sizes.
To better define CNV sizes and boundaries across the human genome, arrays
with small DNA probes have since been designed and used. In one of the
recent studies on genome-wide CNVs, 42 million element array with probe
size approximately 70 base pairs has been employed (Conrad et al., 2010). Key
information that these arrays cannot give is the location of novel duplications.
Now the development of next-generation sequencing technologies has made
it possible to sequence thousands of human genomes in timescales of months
rather than years, and such large-scale projects will not only help in defining
the sequence basis of the already-discovered variants but also discover
others.
CNV Prevalence and Formation
According to the statistics from the Database of Genomic Variants
(http://projects.tcag.ca/variation), there are about 16,000 CNVRs (CNV-
containing regions) and about 67,000 CNVs deposited in the database. While
some CNVs may still be missing, some could be documented twice because of
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inaccurate characterization and others could be very rare, perhaps even one-
off events. It is estimated that CNVs, ranging from 1 kb to several hundred kb,
cover about 12% of the human genome (Stankiewicz et al., 2010). As is true
for all kinds of genomic variation, CNVs mostly include non-coding sequences.
Few include exonic sequences. As Conrad et al.s study has shown, most CNVs
encompass only intergenic sequences, followed in frequency by intronic,
promoter or exon sequences, and lastly whole genes. They are spread across
all the genome and concentrated in those regions that already contain low-
copy repeats, VNTRs, segmental duplications or transposable elements. The
reason for this association is the predisposition of such sequences to result in
structural changes that give rise to CNVs, and because of this predisposition,
such regions (CNVRs) can harbor more than one CNV. Not only that, but to
allow polymorphism to persist there should be no strong negative selection
on copy number variation of such sequences (Nguyen et al., 2008). Thus,
common CNVs most likely represent genomic regions that can vary without
negative consequences, rather than regions positively selected to be in higher
copy numbers. Exceptions may exist. For example, it is theorized that higher
copy numbers of the gene coding for salivary amylase have been positively
selected for in populations depending upon starchy diets (Perry et al., 2007).
Non-allelic homologous recombination between repeated sequences can
result in the formation of CNVs. Other processes include non-homologous end
joining (NHEJ) and microhomology-mediated break-induced repair (MMBIR)
that occur during repair of double-strand breaks in the DNA. The evidence
that these processes create CNVs comes from studying the breakpoints and
sequences surrounding CNVs (Hastings et al., 2009). These genomic changes
can take place during meiosis or mitosis. The ones that occur at mitosis can
either be restricted to one tissue type or present in several or all tissues
depending upon the developmental stage and cell type in which they occur.
For example, somatic mosaicism (Piotrowski et al., 2008) and the observation
of CNVs between monozygotic twins are the result of structural changes
during mitosis (Bruder et al., 2008).
How often are new CNVs formed? This question has been addressed for at
least large CNVs (>100 kb) excluding regions of segmental duplications by a
study looking at >700 transmissions (Itsara et al., 2010). They found an
unexpectedly low rate of 1.2 x 10
-2
CNVs per transmission per generation
compared to CNV prevalence known from higher resolution studies, indicating
that purifying selection removes most large variants from the gene pool.
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CNVs and Phenotypes
Great interest lies in accurately mapping and genotyping CNVs because of
their possible contribution to phenotypic variation, especially disease. There
are two approaches to find a link between CNVs and phenotypes. One deals
with known or already discovered CNVs, and involves studying one or several
CNVs for their phenotypic effects. This is done either by directly correlating
gene copy number with mRNA or protein expression levels (Stranger et al.,
2007) or indirectly by looking for copy number differences between
individuals with phenotypic trait or disease state differences (case-control
association studies) (Hollox et al., 2008). This category would include
commonly polymorphic CNVs that would not be strongly deleterious. The
other approach is to search for CNVs across the genome (which are more
likely to be rare or private variants) that are overrepresented in individuals
with a particular trait or disease as compared to control individuals (Glessner
et al., 2009, Stefansson et al., 2008).
Direct studies of the first kind are difficult to carry out in humans because it is
difficult or impossible to access most living tissues from a cohort of living
subjects for protein level studies. In addition, in cases of multiallelic CNVs,
determining copy numbers accurately is another hurdle (discussed in Section
1.2). However, a study has been done using mice to look at effects of CNV on
transcript levels (Henrichsen et al., 2009). This has shown duplicated genes
that have increased, decreased or unaffected transcript levels. It also showed
that genes included in CNV segments were more likely to have more
restricted, tissue-specific expression than genes never observed in CNVs. This
was not an unexpected observation and is just another way of saying that the
genes more essential to cell function are less likely to tolerate variation. An
interesting example of a CNV not affecting mRNA dosage is of the green opsin
genes (OPN1MW) in humans (Nathans et al., 1986, Vollrath et al., 1988). This
gene can be repeated in tandem on the X chromosome and only the first copy
in the array just downstream of the red opsin gene and promoter region is
transcribed. If the first gene in the array has a loss-of-function mutation in a
male, then no matter how many further copies follow, the person will be
dichromatic (instead of trichromatic).
Several CNVs have been found associated with disease in humans. Large de
novo deletions and duplications that are absent or very rare in the normal
population are commonly found associated with neurodevelopmental defects
like autism, schizophrenia and mental retardation (de Vries et al., 2005, Sebat
et al., 2007, Walsh et al., 2008). De novo CNVs also occur in phenotypically
normal individuals, thus their presence alone is not strong evidence of
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causality. Evidence that the de novo CNVs contribute to these disorders is
either derived by considering the genes included in the CNV segment (e.g.
neurodevelopmental genes) or previous observation of CNV of the same (or
overlapping) region in similar phenotypes. In other cases they are
experimentally verified in functional terms, as for example by gene knockouts
in model organisms (Webber et al., 2009). Low copy number (1 versus 2 or 3)
of a large (~120 kb minimal) CNV was found associated with neuroblastoma
risk (Diskin et al., 2009). This CNV includes the gene NBPF23, member of a
neuron-specific family of genes.
For CNVs that are common and highly polymorphic in the normal population,
it would be natural to think that they do not confer strong negative effects
(Itsara et al., 2009). However, they could possibly contribute to multifactorial
traits and are suspected to be part of the previously unaccounted for genomic
variation (missing heritability) that contributes to a persons predisposition
to complex diseases like heart diseases, diabetes, cancer and Alzheimers, and
variability in response to infectious or genetic diseases and drugs. For
example, a common deletion upstream of the IRGM gene has been found to
confer susceptibility to Crohns disease (McCarroll et al., 2008). Altering gene
dosage of IRGM was found to affect autophagy of internalized bacteria, a
process considered to play a role in Crohns disease development. This
deletion was found indirectly because of LD with a SNP that was found
associated with Crohns disease but was not associated with any coding
sequence variants (Parkes et al., 2007). There is a dearth of such association
studies for complex CNVs because of lack of accurate genotyping methods,
and some that have been published, usually relying on real-time PCR, are
bogged down by measurement inaccuracies (Shrestha et al., 2009). The
following sections discuss this issue in detail.
1.2. Copy Number Assays
The discovery of CNVs has seen a rapid progress in the genomics era with the
sequencing and availability of a more complete human genome and
development of new methods like SNP arrays. Consequently, this particular
kind of structural variation which had largely been unobserved previously
became a strong contender for contribution to human phenotypic and disease
variation. Alongside their discovery it became pertinent that methods to
measure copy number of regions that are variable must be developed to
further study their structure, mutation pattern and phenotypic consequences.
However, discovery and genotyping methods did not develop at the same rate
(Figure 1.2). Whereas simple CNVs involving a deletion or duplication and
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having only two kinds of copy number haplotypes are easily measured,
complex CNVs, like the alpha defensin CNV, that involve multiple copies and
several different kinds of haplotypes require novel approaches. The challenge
then is to accurately measure the number of copies in any given sample,
without which further analysis is either impossible or the ability to get
accurate results is greatly reduced. This does not include highly duplicated
genes, like the ribosomal RNA genes, that range in the hundreds per genome.
The use and power of accurately measuring DEFA1A3 copy numbers for
further analysis will be illustrated later on in this thesis.
Figure 1.2 The difference in the number of CNV regions that have been identified in
the literature and those that have been genotyped in available reference samples.
Figure taken from McCarroll et al. (McCarroll et al., 2007). The WTCCC CNV study
from 2010 has genotyped >3000 CNVs (Craddock et al., 2010)
Two studies have been published that undertook measuring the DEFA1A3
CNV. One of these uses MAPH or Multiplex Amplifiable Probe Hybridization
(Aldred et al., 2005). In this study a set of seven samples was first determined
for their DEFA1A3 copy number by restriction digestion to cut out the repeat
region containing all the repeats the sample contained, then separating and
sizing the two haplotypes from each sample using pulsed-field gel
electrophoresis and Southern blotting. These samples were then used to
calibrate 110 other samples MAPH measurement.MAPH (Armour et al.,
2000) uses probes for a CNV region(s) and reference sequences known to be
2-copy per genome that have a common set of sequences at their ends. Each
probe is designed to vary in length from every other probe used. Genomic
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DNAs of samples are denatured, immobilized on a membrane and the probes
applied. The rationale is that the greater the number of copies of a sequence,
the greater the amount of probe will be bound. The bound probes are then
separated and amplified with a single set of primers which minimizes
differences in amplification rates, and the products are analyzed by
electrophoresis. This allows a measurement of ratios of test to reference
sequence products that correlates with the copy number of test sequence.
MAPH has been shown to be a robust method but a laborious and low-
throughput one. The other study (Linzmeier et al., 2005) used Real-Time PCR,
which is an easy to perform and high-throughput method but the accuracy of
results is unproven at higher copy number. The use of different primer pairs
for test and reference loci may introduce a bias in amplification rates even
with a very careful selection of primers. Even a small bias becomes amplified
after several PCR rounds and renders this method unsuitable for accurate
measurement. Studies have been published comparing CNV genotyping
results from RT-PCR with other more robust methods, proving the generally
low quality and inaccuracy of RT-PCR results (Aldhous et al., 2010, Field et al.,
2009, Fode et al., 2011). The two studies on alpha defensin CNV not only use
different methods but also tested different populations; Aldred et al. reported
a range of 4 to 11, with 7 copies being modal in 111 UK individuals, whereas
Linzmeier et al. reported a range of 5 to 14, with 10 copies being modal, in 24
individuals from five different ethnic backgrounds (6 European American, 6
African American, 6 Asian American, 3 Mexican American and 3 Native
American).
SNP arrays and CGH-arrays can also be used for copy number measurement,
on the principle that the signal from a sequence correlates to its copy number
in the sample. However, standard SNP arrays might not be very useful for
common CNVs, as SNPs within common, complex CNV regions are not
amenable to genotyping and have thus generally been excluded from SNP
databases upon which the array designs are based. For CNV detection and
genotyping special arrays have been designed and software created to detect
and measure CNVs. With arrays using small interrogating probes (<100 bp) the
resolution of structural variation has increased, or in other words, the
breakpoints of CNV regions have become better defined. One study using
aCGH with probes of the size range 70 bp for copy number determination
failed to assign DEFA1A3 copy number classes, among other CNVs, to
individuals due presumably to failure of quality control (Craddock et al.,
2010). This may be due to the comparative nature of the study and failure to
determine the copy number for the reference sample, which can be overcome
if the reference samples copy number has been previously determined by
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other methods. However, arrays are appropriate for genome-wide CNV
studies and not locus-specific studies.
With the development of second-generation sequencing technologies
(Metzker, 2010), it is possible to sequence whole genomes at a great depth
with short read lengths and use it for CNV measurement. The rationale is that
the number of copies of a sequence in the genome will be represented
proportionally in the number of sequenced reads. Thus the Illumina
sequencing platform has been used by one study to detect, measure and
characterize CNVs across the human genome in 159 individuals (Sudmant et
al., 2010). However, not all genomic regions are amenable to such an analysis
due to bias in sequence capture and thus representation or even more
importantly, due to complexity of structure e.g. short read lengths prevent
correct mapping of repetitive sequences and thus although CNVs might be
well-represented in the sequenced reads, they would remain intractable to
further analysis. This method and using CGH-arrays are genome-wide
approaches, but are still not as accurate and easy to perform as PRT, which is
described below.
Other methods that are direct and locus-specific rather than comparative, like
the PFGE experiment for DEFA1A3 by Aldred et al. and FISH, are low-
throughput. They may also be limited by the size of the CNV to be studied.
A locus-specific method that has been shown to combine both accuracy and
high-throughput ability is the Paralogue Ratio Test (PRT) (Armour et al.,
2007). It is a simple PCR-based assay that uses a single pair of primers
designed such that they amplify sequences at both the CNV locus and a
reference locus which is two-copy per genome, with both sequences of
different sizes. One of the primers used is labelled with a fluorescent dye. The
products are separated and analyzed using a capillary electrophoresis system
that detects the fluorescence from the primer and records the amounts of
each product, which are displayed as peaks. Using the relevant software, the
areas of the peaks corresponding to the test and reference loci are obtained
and the ratio of test locus peak area to reference locus peak area is
calculated. This ratio corresponds to the copy number of the test locus in a
given sample, and the ratios of all samples give a linear relationship to their
copy numbers. PRT uses a single pair of primers in a single reaction which
reduces the effects of amplification bias or variable amplification efficiency
between the loci. This is also a comparative method and requires the
determination of copy number for some samples beforehand to be used as
calibrators. It is important that whatever amplification bias between the test
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and reference loci exists, it is the same constant value between calibrators
and test samples. Quality of DNA can affect the rate of amplification. For
example, one site may be a stronger protein-binding sequence than the other
and the presence of residual proteins in the DNA samples could affect the
access of primers in a biased manner between the test and reference loci. In a
similar fashion, amplification bias can come from differences in test and
reference loci sequences that affect the regional topology or melting
temperature of the molecule and hence the access of primers to their
complementary sites. Such differences in flanking sequences can also have
the same effect. Although PRT uses similar sequences from test and reference
loci as templates, this kind of differential can be present and its extent and
effect is an important consideration in the development of a PRT. Despite
these considerations for a PCR-based assay, PRT has been shown to be a high-
throughput, accurate and robust copy number typing method and has been
used for multiallelic CNVs (Walker et al., 2009). Another limitation of this
method is the requirement of the presence of paralogous sequences in the
CNV region that allow such primers to be designed that amplify the CNV locus
and a non-CNV reference locus, and completely exclude any other similar
sequences in the genome.
Table 1.1 Summary of the features of various CNV measuring methods when applied
to complex CNVs.
Method High-
throughput
Accuracy Applicable to
all CNVs
Absolute
Copy
Number
RT-PCR Yes Usually low Yes No
MAPH No High Yes No
aCGH No Variable No No
2
nd
Generation
Sequencing
No Variable No No
PRT Yes High No No
FISH No High No Yes
PFGE No High No Yes
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Besides methods that measure copy number, there are methods that assist in
copy number assignment by providing a ratio between the different copies of
a CNV locus. These ratios are informative of the copy number on the rationale
that a particular ratio is not possible from all copy numbers and thus excludes
some copy numbers from consideration. For example, obtaining a ratio of 3
would mean a total copy number of 4 (3:1) or 8 (6:2) or higher multiples of 4.
Restriction Enzyme Digestion Variant Ratios (REDVR) is one such method that
uses multisite variants (MSVs: single nucleotide differences between the
repeats of a CNV sequence) that are part of restriction enzyme recognition
sites and digestion with the enzyme post-PCR amplification results in two
kinds of products, the ratio of which is useful. Three such assays for the
DEFA1A3 CNV locus were used by Aldred et al (Aldred et al., 2005). Similarly,
small indel polymorphisms between repeats can be used. In this case just a
simple PCR across the indel gives two kinds of products on the basis of size,
and their ratio is useful. Similarly, the presence of amicrosatellite in a CNV
sequence allows the ratios of microsatellite alleles to be used as informative
for total copy number of the CNV. Microsatellites are highly variable and can
be very informative, but are prone to PCR slippage. The frequency of the
minor allele in the case of indels and MSVs must be considered before the
design of the assay to make sure it will be informative in most of the samples.
1.3. The Defensin Peptides
A class of AMPs
Defensins, as the name suggests, are antimicrobial peptides (AMPs) that
provide immunity or defence against microbes. They are only one of several
classes of AMPs found in plants, animals, fungi and bacteria, but the most
prevalent one. AMPs are different from classical antibiotics in that they are
products of protein synthesis from mRNA templates and so their structure is
encoded in their respective genes. These are grouped into different classes on
the basis of their structure. A characteristic structure of the defensins is the
presence of two or more disulphide bridges, and thus four or more Cysteine
residues, and a beta-sheet folding of the peptide. They are small (3 to 6 kDa),
cationic peptides with much diversity in peptide sequence, antimicrobial
properties and in the case of multicellular organisms, site of expression
(Diamond et al., 2009). Their pervasive prevalence and diversity reflect their
importance in providing immunity to host organisms.
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Mode of Microbicidal Activity
Defensins, like other AMPs, exert their microbicidal effects mainly by inserting
into and disrupting cell membranes, thereby causing the lysis of cells. They do
this by forming pores that cause leakage of ions and larger molecules across
the membrane, disrupting electrolytic balance and cell homeostasis (Wimley
et al., 1994). Their specificity for bacterial cells is due to the net anionic charge
of the bacterial surfaces, whereas animal cells have relatively neutral surfaces.
This mechanism makes them effective against enveloped viruses as well.
Defensins are amphipathic, which means they possess both hydrophilic
regions to interact with the charged surfaces of microbes and hydrophobic
regions that allow their insertion in lipid membranes. Defensins have an
overall cationic charge and the artificial replacement of the cationic residues
with uncharged amino acids decreases their ability to kill bacteria (Zou et al.,
2007). The cationic charge allows their interaction with the anionic surface
charge and non-polar residues facilitate insertion into the lipid bilayer.
Whereas this appears to be the major mode of action, there is evidence that
defensins, like alpha-defensin 1 from humans, can inhibit DNA, RNA and
protein synthesis within bacterial cells (Brogden, 2005). The specific mode of
action is thought to vary depending upon both the peptide and the microbe in
question. Defensins have been found to be salt-sensitive with reduced activity
at higher salt concentrations (Goldman et al., 1997). Recently, it has been
shown that a human beta-defensin peptide (hBD-1) that is constitutively
expressed by the epithelial tissue has increased antimicrobial activity when its
disulphide bonds are lost by reduction and that reduced hBD-1 is present in
intestinal crypts and skin epithelia (Schroeder et al., 2011). They also tested
hBD-3 under reducing conditions for bactericidal activity and found reduced
bacterial killing. Thus, whether there are other defensin peptides that may
have enhanced microbicidal activity under reducing conditions or whether
this mechanism is reserved for hBD-1 remains to be investigated.
Defensin sub-classes
Several defensins have been identified in plants, invertebrates, like
arthropods and molluscs, and in vertebrate animals, and are continuing to be
discovered. In the literature these are classified according to the organism in
which they are found like insect defensins, plant defensins etc. The defensins
in vertebrates, especially mammals, on the other hand are much better
studied, and these are further divided into three classes based on their
structure (and hence phylogeny), rather than being named after their host
organism.
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Thus in vertebrates, on the basis of arrangement of disulphide bonds and the
length of the peptide between them, defensins are sub-divided into alpha,
beta and theta defensins. Alpha defensins have disulphide linkage between 1
and 6, 2 and 4, and 3 and 5 Cysteines, beta defensins have between 1 and 5, 2
and 4, and 3 and 6 Cysteines, and theta defensins are cyclic with no free end
but contain the three disulphide bonds (Figure 1.3) (Ganz, 2003).
Figure 1.3Disulphide linkage characteristic of the three classes of primate
defensins in their mature forms. The six Cysteines form disulphides in the
order 1-6, 2-4, 3-5 for alpha defensins (30 amino acid mature Human
Neutrophil Peptide-3 as example), 1-5, 2-6, 3-4 for beta defensins (42 amino
acid mature Human Beta Defensin 2 as example), and a cyclic structure for
theta defensins (18 amino acid Rhesus Theta Defensin as example). Figure
modified from Ganz et al. (Ganz, 2003)
Theta defensins are formed by the ligation of two alpha-defensin related
peptides (Tang et al 1999).
Vertebrate Defensins
ɽ-defensins have only been identified in non-hominid primates, whereas ɲ-
defensins have only been identified in Euarchontoglires (primates, rodents
and lagomorphs). Defensins identified in all other vertebrates are ɴ-defensins.
Given the structural similarity of non-vertebrate and plant defensins to ɴ-
defensins, it seems obvious that these are the ancestral defensins that have
given rise to ɲ-defensins in mammals. Theta-defensins have only been found
to be active in some non-human primates, with pseudogenes present in other
primates, including humans. They are thought to have arisen from mutations
in the genes coding for alpha-defensins in Old World monkeys (Nguyen et al.,
2003). Thus these fast evolving peptides have also evolved differences in
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tissue expression. The following table shows differences of expression sites
between the defensins and between different mammals.
Figure 1.4 Table taken from Ganz et al. (Ganz, 2003)
Studies on the amino acid sequences of these peptides and their secondary
structures seem to show that the beta-defensins are evolutionarily more
closely related to insect defensins than alpha-defensins, although it is not a
perfectly clear picture (Hughes, 1999). This study by Hughes was prior to the
availability of genome sequences of animals and he argues that although
alpha and beta defensins have similar triple-stranded beta sheet structures,
and their gene clusters are physically linked, both being present within a 100
kb of each other on chromosome 8, these are by no means conclusive
grounds for inferring that they are related. Hughes has argued that the
simultaneous and independent evolution of similar protein motifs occurs in
evolutionarily non-related but functionally related genes, and close linkage,
although common in closely related genes, is not an evidence of being related.
After the availability of genome sequences from various animal species,
studies on the genomic clustering of defensin genes as well as comparison of
amino acid and nucleotide sequences have led to the hypothesis that alpha-
defensin genes originated from a beta-defensin gene precursor and that the
theta-defensin gene originated from mutation in an alpha-defensin gene (Xiao
et al., 2004).
Defensins in HumansȾ-defensins
Seven ɴ-defensins have been identified in humans at the protein level of
expression, and a further 16 at the mRNA level. They are mainly expressed in
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the epithelial cells of various tissues including respiratory tract, urinary tract,
kidney, intestine, skin, conjunctiva, pancreas and testis. At least two ɴ-
defensins have been identified only in the epithelia of testis and epididymis,
whereas the others have a range of tissue expression (Pazgier et al., 2006).
Their expression can be constitutional or induced. The control of their
expression is not very well understood, but microorganisms or their structural
components are known inducers and host molecules recognizing them are
mediators of this induction (Kolls et al., 2008).
Function and Role in Psoriasis
The function of ɴ-defensins in infection and providing immunity is well
documented. They have been shown to be effective in vitro against bacteria
such as E. coli and S. aureus and fungi such as C. albicans (Vylkova et al.,
2007). Besides being antimicrobial, defensins also have other immunity-
related functions. Beta-defensins have been shown to induce the production
of cytokines, and also to act as cytokines themselves (Niyonsaba et al., 2007).
They induce proliferation and migration of keratinocytes, production of pro-
inflammatory cytokines and thus are thought to be players in the wound
healing process. In fact human ɴ-defensin 2 (HBD-2) was first isolated from
psoriatic lesions (Harder et al., 1997) and whereas on the one hand they
prevent the infection of these autoimmune lesions, a higher copy number of
their genes has been associated with psoriasis (Hollox et al., 2008), making
them a contributor to the development of this disease possibly because of
their ability to enhance inflammation.Ƚ-defensins
Six alpha defensins have been identified in humans. Their sizes range from 29
to 34 amino acids. Unlike the beta-defensins there is no discrepancy between
the number of genes, mRNA transcripts and proteins identified for alpha-
defensins except for alpha-defensin 2 (DEFA2). It is thought to be a proteolytic
cleavage product of either or both of DEFA1 and DEFA3, as no gene/transcript
has been found for it. DEFA1, 2, 3 and 4 (also known as Human Neutrophil
Peptides or HNPs 1-4) are produced in the neutrophils, and DEFA5 and 6 (also
known as Human Defensins or HDs 5 and 6) are produced in the Paneth cells
of the small intestine. The production of DEFA1-4 takes place in
promyelocytes, the precursor cells of neutrophils in the bone marrow, where
they are packaged into azurophilic granules (Date et al., 1994). No further
synthesis of defensins takes place in mature neutrophils. These granules in
the mature neutrophils fuse with phagocytised vacuoles containing
pathogens, allowing defensins access to them.
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(DEFA1) ACYCRIPACIAGERRYGTCIYQGRLWAFCC
(DEFA3) DCYCRIPACIAGERRYGTCIYQGRLWAFCC
(DEFA2) CYCRIPACIAGERRYGTCIYQGRLWAFCC
(DEFA4) VCSCRLVFCRRTELRVGNCLIGGVSFTYCCTRVD
(DEFA6) FTCHCRRSCYSTEYSYGTCTVMGINHRFCCL
(DEFA5) ATCYCRTGRCATRESLSGVCEISGRLYRLCCR
nthesis
These defensins, as all others, are produced as inactive pre-prodefensins,
which in the case of DEFA1 is 96 amino acids long. This includes an N-terminal
signal peptide, an anionic propiece and the mature defensin. The signal
peptide directs it to the endoplasmic reticulum from where it is packaged off
into granules. This is cleaved to give the propeptide, 56 amino acids long. It is
not known which enzyme(s) processes neutrophil defensins into their mature
forms. The enteric alpha defensins were shown to be cleaved into their
mature forms by Paneth cell trypsin (Ghosh et al., 2002). The propeptide is
then finally cleaved to give the mature defensin peptide (DEFA1), 30 amino
acids long. Studies have found other intermediate-sized peptides that are
larger than the mature peptide but of a different size than the pre-
prodefensin and prodefensin. However, these precursor and intermediate
peptides are found in minute quantities in the cell (0.25% of total defensin
content) (Harwig et al., 1992).
Antimicrobial Properties
Human alpha defensins are effective against bacteria, fungi and viruses, not
just by direct microbicidal activity but also through the recruitment and
modulation of other immune cells and functions. Each exhibits a different
level of specificity for microbes. For example, DEFA4 and 5 are more potent
against gram-negative bacteria like E. coli, whereas DEFA4 is least potent
against gram-positive S. aureuswhereas DEFA2 and DEFA5 are most effective
(Ericksen et al., 2005). DEFA1-3 have also been shown to neutralize toxins
from B. anthracis and C. difficile (Giesemann et al., 2008, Kim et al., 2005).
DEFA1-3 can inactivate Herpes Simplex virus and DEFA1 can inactivate
influenza, vesicular stomatitis and cytomegalovirus (Daher et al., 1986). This
Figure 1.5 Amino acid sequences of 6 human alpha defensins in their
mature form with the six Cysteines in each peptide underlined
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direct inactivation is only seen against enveloped viruses, but indirect activity
against non-enveloped viruses also exists via modulation of virus-infected
cells (Klotman et al., 2006). DEFA1 can also kill T. cruzi, the protozoan parasite
causative of Chagas disease (Madison et al., 2007). Experiments whereby
mice expressing HD-5 gene were compared with non-transgenic mice in their
ability to protect from infection by Salmonella, showed the effectiveness of
this defensin (Salzman et al., 2003).
Immunomodulatory Properties
The neutrophil defensins have been shown to facilitate phagocytosis, induce
histamine release and inhibit the complement pathway (Befus et al., 1999,
Groeneveld et al., 2007, Soehnlein et al., 2008). They have also been shown to
be anti-inflammatory when released by apoptotic neutrophils (Miles et al.,
2009). They exert this effect by inhibiting the release of pro-inflammatory
cytokines by macrophages even in the presence of bacteria and without killing
the macrophages. Of course these activities are demonstrated in vitro or at
best in murine models and thus how significant they are in vivo remains
questionable. Moreover, mice do not express alpha defensins in their
neutrophils. However, a study has been done looking at mice knockouts for
Defb1, a beta defensin that is expressed normally in murine lungs (Morrison
et al., 2002). No overt deleterious phenotype in these mice was observed
except that they harboured a greater load of Staphylococcus bacteria in their
urinary bladder than control mice.
DEFA1-3 have been shown to inhibit the differentiation of monocytes into
macrophages, and this property may be responsible for part of the phenotype
in Chronic Myeloid Leukemia where large amounts of these peptides are
released by dysplastic granulocytes (Droin et al., 2010).
1.4. Human Alpha Defensin Genes and
their CNV
There are five known alpha defensin genes in humans, DEFA1, DEFA3, DEFA4,
DEFA5 and DEFA6, all located on chromosome 8p23.1. Since all these except
DEFA3 have syntenic orthologues in the chimpanzee genome, and since
DEFA3 varies from DEFA1 by a single base pair change, DEFA3 is thought to
have arisen in humans via a mutation in the DEFA1 gene. This single base pair
change (C to A) results in changing the first amino acid in the mature peptide
from Alanine (GCC) in DEFA1 to Aspartic Acid (GAC) in DEFA3. Moreover,
these two genes share a common locus such that any given copy can either
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have DEFA1 or DEFA3. This locus has thus been termed DEFA1A3 and is part
of a 19kb copy number variable block (Aldred et al., 2005). This tandemly
repeated 19kb DNA block also includes a theta defensin pseudogene (Figure
1.6). A 10kb partial version of this block, not including the pseudogene, is
present in one copy per chromosome 8 from observations so far. There is only
one reported partial deletion of this locus on dbSNP catalogued as
rs71776817; however there is no information on its frequency or validation.
Thus the copy number of the DEFA1A3 locus is taken as the combined copy
number of the 19kb repeat block (termed full repeat) plus the 10kb partial
repeat.
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Figure 1.6 The Human alpha defensin gene cluster on chromosome 8p23.1 drawn to scale. The 19 kb full repeat is copy number variable with numbers ranging
from 0 to 6 in European haplotypes. The 10 kb partial repeat is not known to vary in copy number. Both contain a copy of DEFA1A3.
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The DEFA1A3 CNV was discovered while making an attempt to characterize
the genes coding for DEFA1-3 and to find whether DEFA1 and DEFA3 are
products of alleles or separate genes (Mars et al., 1995). The copy number
variable status of this locus complicates this definition. MAPH-based
measurements of DEFA1A3 in 111 European individuals using 7 calibrators
typed with restriction digestion, pulsed-field gel electrophoresis and Southern
blotting has shown a copy number range from 4 to 11 copies (Aldred et al.,
2005). From this same study DEFA3 has been found to vary from 0 to 4 copies;
10% of the people tested did not have the DEFA3 gene.
Figure 1.7 Copy numbers of DEFA1, DEFA3 and total (DEFA1+DEFA3) and their
frequencies in 111 Europeans as measured by MAPH (figure taken from Aldred et al.
2005)
The percentage of individuals without DEFA3 is between 10% and 15% in
European and Asian (Chinese/Japanese) populations and about 37% in the
African population (Ballana et al., 2007). This means that any given
chromosome 8 can have from 1 to 6 copies of DEFA1 and from 0 to 2 (or
maybe 3) copies of DEFA3. Their arrangement in the array of 19kb repeats
remains elusive. DEFA3may have a propensity to be present at one or the
other end of the array, or due to recombination and gene conversion events it
27
could be completely randomly situated. This idea of repeat array structure
was investigated by Aldred et al. using long PCR to assay the end repeat
positions for DEFA1A3. It was found that although DEFA3was more likely to
be at the 5 end (centromeric end) of the repeat array, it was found within the
array and not on an end repeat more than half the time. They also
investigated the copy number for DEFA1 in other primates using MAPH and
found high copy numbers like 8 in chimpanzee, 11 in orang-utan, 3 in gorilla
and 5 in gibbon. They only typed a single individual of each species. From
array CGH experiments, CNV of the chimpanzee chromosome 8 region
orthologous to the alpha defensin cluster of humans has been observed
(Perry, Yang et al., 2008). This implies that the alpha defensins have been copy
number variable since before the divergence of humans and chimpanzees,
and possibly much earlier. Twelve functional alpha-defensin genes in the
marmoset sequenced genome have been identified from comparative analysis
with human and other primate sequences (Das et al., 2010). Marmoset is a
NewWorld Monkey (platyrrhine) and is thus a representative of this group of
primates. If these 12 genes are indeed functional, then they represent either
12 unique alpha-defensin genes or include copy number variable genes, like
the DEFA1 gene in humans and chimpanzees.
For the rest of the alpha defensin genes in humans, there is no known copy
number variation except for a deletion polymorphism of DEFA4. This is a 7 kb
deletion encompassing the entire gene and is catalogued as rs71926333 on
dbSNP. This deletion has resulted from the non-allelic cross-over between a
300 bp sequence on its centromeric end and a duplication of this sequence on
the telomeric end. As the results from this work have shown (see Section
2.10), this is a rare deletion.
1.5. Alpha Defensins and Disease: Effect
of CNV
Due to their anti-infective and immunomodulatory properties, the defensins
have been hypothesized and investigated as possible contributors to various
diseases especially those of an autoimmune nature. These are diseases with
several but unknown contributing factors. In the case of psoriasis, ɴ-defensin
has been shown to have a role as cited earlier. Such studies either look for
correlation between peptide levels and disease, or between gene copy
number polymorphism and disease.
A study looked at levels of neutrophil ɲ-defensin and a beta defensin in
plasma of systemic lupus erythematosus (SLE) patients as compared to
healthy controls (Sthoeger et al., 2009). They found significantly higher alpha-
28
defensins in patients versus controls, and also found a link with severity of
disease. No significant correlation was observed for the beta defensin. SLE is
an autoimmune disease that affects various tissues and organs in the body
but with varying symptoms. The underlying cause is not known. Whether high
defensin levels contribute to disease severity or are just an effect remains
unanswered. If higher defensin levels do have a link to disease severity, it
might be associated with higher genomic copy numbers which would give
more confidence in the association. Another possibility could be that defensin
levels do matter but are more a function of neutrophil count or defensin
induction than genomic copy number.
Since defensins have been shown to have reduced antimicrobial activity at
high salt concentrations, their role in cystic fibrosis has been hypothesized
and in the case of beta defensins, has been studied. Cystic fibrosis (CF) is a
monogenic, autosomal recessive disease but shows great variability in
phenotype. The respiratory tract is the mainly affected system, resulting in
recurrent and chronic infections, inflammation, clogging of airways and
fibrosis of tissue. However the severity of lung disease is the most variable
phenotype even within patients harbouring the same mutation (Davis, 2006).
This points to the existence of other genetic factors that modify disease
outcome. Beta defensins are expressed in the epithelial cells of the airways
and high salt concentrations of CF patients mucus would inactivate them. No
association between beta defensin CNV and CF disease severity was observed
(Hollox et al., 2005).
There has been considerable interest in the link between defensins in the
gastrointestinal tract and inflammatory bowel diseases (IBDs). Antimicrobial
peptides are accepted to play an important role in maintaining the normal gut
flora. While DEFA5 and 6 are normally produced in the intestinal epithelial
cells, expression of DEFA1-4 has been observed in active IBDs like Ulcerative
Colitis and Crohns disease (Cunliffe, 2003). Neutrophil migration into
intestinal tissue during inflammation is also a source of these defensins. On
the other hand, reduced DEFA5 expression has been linked with Crohns
disease (Ramasundara et al., 2009). Despite these studies nothing conclusive
can be said of their role in IBDs although some role seems likely.
There has been no study attempting to associate DEFA1A3 CNV with these
diseases, the reason most likely being absence of reliable typing methods.
From conflicting findings on beta defensin CNV and Crohns, where one study
associated lower (Fellermann et al., 2006) and another higher (Bentley et al.,
2010) CNs with disease, it is quite clear that inaccurate typing can lead to false
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associations. A thorough study using PRT has shown no significant association
between beta defensin CNV and Crohns disease (Aldhous et al., 2010).
The WTCCC CNV study is a large-scale study of genome-wide CNVs using
array-CGH in thousands of cases of 8 complex diseases, including Crohns
disease and rheumatoid arthritis (Craddock et al., 2010). However, the list of
CNVs they successfully genotyped does not include the DEFA1A3 CNV.
However, they genotyped the beta defensin CNV and from well-powered
analysis showed that it has no association with Crohns disease. Essentially,
the role of the DEFA1A3 CNV in diseases, if any, remains unexplored, and it
even remains unknown how gene copy number polymorphism affects alpha
defensin protein levels. There is one published study looking at neutrophil
defensin amount and DEFA1A3 copy number, and shows eight such
measurements with a general increase in protein amount with increasing copy
number (Linzmeier et al., 2005). As mentioned earlier there are reasons to not
have high confidence in the copy numbers measured by real-time PCR for
highly variable loci such as DEFA1A3 as has been done by Linzmeier et al.
1.6. Aims of This Thesis
In this study, the primary aim was to develop a multi-assay PRT-based
measuring system for assaying the multiallelic DEFA1A3 CNV in the European
population. Due to the non-availability of extensive genomic sequence
variation information for human populations other than the Europeans at the
time, it was of secondary interest to see how well this system worked in the
HapMap Asian (Chinese and Japanese) and African (Yoruban) samples.
The second aim was to study the haplotypes of this locus in Europeans and
obtain an estimate for the mutation rate of this CNV. Segregation information
of this locus in three-generation CEPH families would allow an estimate of its
mutation rate and definition of existing European haplotypes in terms of copy
number. Copy number haplotypes of first generation individuals in these
families can be defined further by combining them with their SNP genotypes
in the same LD block (from the HapMap database).
A third aim was to test for potential functional consequences of this CNV.
Given that the primary role of these peptides is in defence against infections
due to their antimicrobial nature, a system for studying the effects of this CNV
on resistance to infection is needed. Cystic Fibrosis (CF) patients provide such
a system where all patients, despite the same CF-causing mutation, present
with a highly variable infectious state phenotype. Thus it was aimed to test
whether copy number of this locus associates with lung disease in CF.
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Finally, it was aimed to develop a protocol for testing the relationship
between gene copy number and expressed protein levels in neutrophils.
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2. METHODS ANDMATERIALS
2.1. Copy Number Measurement Assays
PRT MLT1A0
This PRT makes use of an LTR sequence in the Full Repeat unit, which is
dispersed across the genome and thus provides paralogous sequences to be
used as reference. Primers have been designed that amplify specifically across
the MLT1A0 copy in the alpha defensin repeats and across a similar sequence
on chromosome 1 (Figure 2.1). The PCR products from the two sites differ in
length by 3 base pairs which allows their separation via capillary
electrophoresis. This PRT excludes the Partial Repeat unit and thus we assume
that the copy number measured is two less than the total copy number of
DEFA1A3.
The forward primer has been used labelled with two fluorescent dyes, FAM or
NED. Two separate PCRs are carried out for each sample; one employs the
forward primer labelled with FAM and the other with NED. This gives two
measurements for each sample, the average of which is finally used in the
analysis. Using two separate dyes means that both PCR products for each
sample can be analyzed in a single electrophoretic capillary, instead of
performing the PCR twice for a single dye and then using two separate
electrophoretic lanes for their analysis.
The 5 to 3 primer sequences are as follows:
MLT1A0-F: FAM/NED-CCCAGAGAGCTCCTTC
MLT1A0-R: GTGACTTATAAACAACAAAAA
PCR:
23 cycles of:
1. 95ȗC for 30 seconds
2. 51ȗC for 30 seconds
3. 70ȗC for 30 seconds
1 cycle of:
4. 70ȗC for 30 minutes
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Figure 2.1 Predicted PCR products from PRT MLT1A0 primers and their corresponding
peaks obtained after capillary electrophoresis. The genome assembly used has two
full and one partial repeat, and these primers amplify only from the full repeats and
the reference sequence on chromosome 1.
PRT DEFA4-406
This PRT has been developed employing the sequence similarity between the
DEFA1A3 genes and the paralogous DEFA4 gene. Unlike PRT MLT1A0, this PRT
measures all copies of the gene because the primers amplify across the gene
itself. However, the similarity in sequence also meant that designing a PRT in
which the products sufficiently differed in size was not possible. The products
from the two loci differ by only 2 bp (404 and 406 bp). These are not
separated sufficiently on electrophoresis (Figure 2.2), and therefore a
restriction digestion step has been included that uses the enzymeMspI, which
cuts both PCR products but at different positions resulting in 275 and 317 bp
products.
Only a single dye has been used for this PRT (HEX).
The 5 to 3 primer sequences are as follows:
DEFA4-406-F: TGCTCCTGCTCTCCCTCCT
DEFA4-406-R: HEX-TTGGAATCAAGTCTTTGGAGAAA
PCR:
26 cycles of:
1. 95ȗC for 30 seconds
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2. 56.5ȗC for 30 seconds
3. 70ȗC for 30 seconds
1 cycle of:
4. 70ȗC for 30 minutes
MspI digestion:
5ʅl PCR product + 10ʅl buffer/enzyme mix (3 Units enzyme per reaction)
Incubate overnight at 37ȗC.
Figure 2.2 Predicted PCR products from PRT DEFA4-406 primers, their corresponding
overlapping peaks after electrophoresis and well separated peaks after digestion
withMspI and electrophoresis.
Calibrating the PRTs
A set of 7 samples has been used to calibrate the ratios obtained from both
PRTs and convert the ratios to copy numbers. These samples range in copy
number from 5 to 9 which were ascertained using restriction digestion, pulsed
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field electrophoresis and Southern blotting (Aldred et al., 2005). Thus these
samples were included in every PRT test performed.
2.2. Copy Number Validating Assays
(Allele Ratio Assays)
Indel-5 Assay
A 5 bp insertion/deletion polymorphism in the alpha defensin repeats was
identified from the NCBI trace archive sequences. The ratio of sequences
containing the 5bp to those not containing it in the archived traces was about
1 to 2.5. Primers were designed to make a product across this polymorphism
of size 124 bp from the shorter repeats and 129 bp from the longer ones. This
assay includes both the full and partial repeats.
The forward primer has been labelled using two dyes, HEX or NED.
The primers are as follows:
Indel-5-F: HEX/NED-CTGTCCAGGAAGAGGGAGAG
Indel-5-R: CAGCTGGAGGGTCTCTGTTC
PCR:
24 cycles of
1. 95ȗC for 30 seconds
2. 57ȗC for 30 seconds
3. 70ȗC for 30 seconds
And 1 cycle of
4. 70ȗC for 30 minutes
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Figure 2.3 Predicted PCR products from Indel-5 primers and actual peaks obtained
from capillary electrophoresis. The 5bp Indel sequence, in bold and underlined, is
present in only one of the repeats on the genome assembly.
DefHae3 Assay
This assay has been described elsewhere (Aldred et al., 2005). The primers
used amplify across the single base pair that differs between the DEFA1 and
DEFA3 genes and alters the first codon in the mature peptides coding
sequence from GCC to GAC so that the N-terminal Alanine in DEFA1 changes
to Aspartic Acid in DEFA3. This base is part of a HaeIII recognition site in
DEFA1, which is lost in DEFA3. Digestion of PCR products with this enzyme
results in two different sized products. One of the primers has an introduced
mismatch to create a constant HaeIII recognition site to act as a control for
completeness of digestion (underlined base below). The reverse primer is
tagged with the fluorescent dye FAM.
DefHae3-F: TGTCCCAGGCCCAAGGAAAA
DefHae3-R: FAM-TCCCTGTAGCTCTCAAAGCA
PCR
24 cycles of:
1. 95ȗC for 1 minute
2. 58ȗC for 1 minute
3. 72ȗC for 1 minute
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HaeIII digestion
5ʅl PCR product + 10ʅl enzyme/buffer mix (0.75 Units enzyme per reaction)
Figure 2.4 Predicted PCR products from DefHae3 primers and actual peaks obtained
from capillary electrophoresis after digestion of PCR products with HaeIII. The 4bp
HaeIII recognition sequences, in bold and underlined (GGCC), are present in the
primer sequence as a check for digestion and also present in the internal sequence in
case of DEFA1 genes but destroyed in DEFA3 genes due to the base substitution of C
to A (highlighted in red).
Since only a single base differs between the two products of this assay, they
have the potential to form heteroduplexes late in the PCR. These are then not
cleaved at the distinguishing site by HaeIII in the digestion reaction. When
made single stranded again for electrophoresis, all molecules of
heteroduplexes, both DEFA1 and DEFA3 products, are thus the size expected
from DEFA3. This causes a shift in the ratios obtained from the peaks towards
more DEFA3 than actual. When looking at ratios of DEFA1 to DEFA3, the ratios
are systematically lower than expected, by a factor of about 15%, presumably
due to failure of heteroduplex to digest with HaeIII (Figure 2.5). When
analyzing results, this error has to be accounted for.
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Figure 2.5 Graph showing deviation of obtained DEFA1 to DEFA3 ratios from expected
ratios
2.3. Capillary Electrophoresis
The PCR products from both PRTs and both Allele Ratio assays were analyzed
using the ABI 3100 Genetic Analyzer, which separated the single-stranded
products via capillary electrophoresis and quantified the amounts via
fluorescence detection. Three different fluorescent dyes, FAM, HEX and NED,
have been used to label the primers. To prepare the samples for analysis they
were added to 10ʅl mixture of HiDi Formamide and ROX-labelled markers
(ratio of 170ʅl to 2ʅl for sixteen samples) and heated at 96ȗC for 3 minutes to
ensure separation of DNA strands. The amount of sample added and
electrophoresis variables used were different for different assays and are
given below:
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Assay PCR product
used (Ɋl) Voltage (kV) Injection Time(sec)
PRT MLT1A0Ƚ 0.7 each of FAM
and NED
1 30
PRT DEFA4-406Ⱦ 1 1.5 30
Indel-5Ƚ 0.5 each of HEX
and NED
1 30
DefHae3Ⱦ 1.5 1.5 30Ƚ: These were combined in later assays and run together
ɴ: These were combined in later assays and run together
2.4. Assigning Copy Numbers
Maximum Likelihood Program
The copy number assigned to each sample (Most Likely Copy Number: MLCN)
is the consensus of the four assays described previously. This was done using
a computer program (written by Prof. John Armour) that calculated the
likelihood of all possible copy numbers (3 to 13 for European samples) for
each sample, and took into consideration unrounded copy numbers measured
from both PRTs, the standard deviation for each copy number measurement
for each PRT and the peak areas from the allele ratio assays. The likelihood of
each copy number given the population frequency is not included in the
calculation for maximum likelihood (i.e., an assumption of flat priors is
used). For each sample a minimum ratio is calculated which is the ratio of the
likelihood of the most likely copy number (always 1) to the likelihood of the
second most likely copy number. Thus, a high minimum ratio means higher
confidence in the copy number assigned because the next most likely copy
number has a low likelihood.
DefHae3 data was corrected before adding to the program. The percent
deviation from expected ratios for different ratios was calculated and
averaged across the same ratios. Apart from an expected ratio of 1 between
DEFA1 and DEFA3, the percent deviation was found to be about 0.16 or 16%
for other ratios. The actual average including expected ratios of 1 came to be
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at 0.155 and excluding ratios of 1 came to be 0.167. Thus all peak areas for
DEFA1were multiplied by 0.15 and added back to the unaltered peak areas
for correction, as they are on average 0.15 times less than the actual due to
reasons discussed in the DefHae3 assay description.
2.5. DEFA1A3 del Assay
This assay is a simple PCR with primers designed to test for the presence of a
580 bp deletion in the DEFA1A3 locus catalogued on the database as a SNP,
rs71776817.
The 5 to 3 primer sequences are as follows:
DEFA1A3 del-F: AAGCTCAGCAGCAGAATGC
DEFA1A3 del-R: CTTGCATGGGACGAAAGCTT
Expected product size from the undeleted copies is 727 or 731 bp, depending upon
another 4 bp polymorphism in the locus, and from the deleted version is 147 or 151
bp.
PCR
95ȗC for 3 min
36 cycles of:
95ȗC for 30 sec
63ȗC for 30 sec
70ȗC for 30 sec
Products were analyzed by electrophoresis on an agarose gel.
2.6. Correlation with microarray data
A human genome-wide copy number variation study using high-resolution
Comparative Genome Hybridization was undertaken by the Genome
Structural Variation Consortium (Conrad et al., 2010). The array used
contained 42 million oligonucleotides, and 20 individuals of European
ancestry and 20 of African were analyzed in comparison to a European
individual. The data, binary logarithms of hybridization ratios, was made
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available online after quality control and normalization
(http://www.sanger.ac.uk/cgi-bin/humgen/cnv/42mio/downloadBigDB.cgi).
The reference individual and 18 tested individuals (9 European and 9 African)
were part of the HapMap sample sets typed for DEFA1A3 copy numbers (see
Chapter 3). Copy number variation of the DEFA1A3 containing repeat could be
observed just by plotting the values for the probes covering this region on a
graph (Figure 2.6). This gives a noisy picture, but if the median for each three
consecutive values is taken, and then the average of ten of the medians is
used, a clear picture of gain or loss is observed. For comparison of the data
with the measured copy numbers the average of the log2 ratios for all probes
covering the alpha defensin repeat region could be calculated and predicted
to have a correlation with measured copy numbers. Inversely, the anti-log of
the averaged values of a sample could be predicted to be similar to the ratio
of that samples copy number to the reference samples copy number (see
Chapter 3).
Figure 2.6On the left are the plots of the raw data for the probes covering the region
chr8: 6,816,648-6,867,537, and on the right are the averages of the medians for the
same region in the same two samples.
(This analysis makes use of data generated by the Genome Structural
Variation Consortium (PIs Nigel Carter, Matthew Hurles, Charles Lee and
Stephen Scherer) whom we thank for access to their CNV discovery and
genotyping data, made available through the websites
http://www.sanger.ac.uk/humgen/cnv/42mio/ and
http://projects.tcag.ca/variation/ as a resource to the community.)
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2.7. Segregation Analysis
Three-generation CEPH pedigrees were typed with the four assays for the
purpose of inferring haplotype copy numbers of DEFA1A3 on the principle of
segregation of chromosomes from parents to offspring. The assignment of
haplotype copy numbers was done manually based on measured diploid copy
numbers, diploid Indel-5 copy numbers, diploid DEFA1/DEFA3 copy numbers
and segregation information from surrounding markers. Counterintuitively,
high diploid copy numbers, such as for the DEFA1A3 locus, rarely present with
a situation where more than one combination of haplotypes is possible in the
parental generation given the availability of a large number of children,
exhibiting, usually, all four possible combinations of haplotypes. For example,
consider diploid copy numbers of 5 and 3 for a hypothetical locus in a set of
parents who have children with four different diploid copy numbers of 2, 3, 5
and 6. In this scenario, two sets of haplotypes in the parents can be possible:
2+3 and 0+3, and 4+1 and 2+1. As diploid copy numbers increase (e.g., to a
range such as that exhibited by DEFA1A3), possible haplotype combinations
decrease to usually one possibility. An example is presented in Figure 2.7.
Figure 2.7 CEPH Family 1408. Measured diploid copy numbers within symbols and
haplotype copy numbers outside. Black shows non-transmitted haplotypes in
generation I. Red haplotypes in generation III inherited from father and grey
haplotypes from mother.
In Figure 2.7 DEFA3 and Indel-5 alleles copy numbers are not shown,
although they are also useful for haplotype sorting and their own haplotype
copy numbers can also be inferred in a similar manner. As shown in Figure 2.8,
the DEFA3 (and hence also the DEFA1) haplotype copy numbers were easily
assigned based on the measured diploid copy numbers of these genes from
the DefHae3 assay. The DEFA3 diploid copy numbers were arrived at given the
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MLCN for each sample, e.g. a DEFA1 to DEFA3 ratio of 1 for a sample with
total copy number of 4 results in assigning 2 DEFA3 copies to the sample (as is
true for the maternal grandmother in the figure below, who has a total copy
number of 4 and a DEFA3 diploid copy number of 2).
Figure 2.8 CEPH Family 1408. The diploid DEFA3 copy numbers are shown below the
symbols in black. The haplotype DEFA3 copy numbers are given in brackets next to
the total haplotype copy numbers in generation I and II.
Similarly the Indel-5 alleles copy number from the Indel-5 allele ratio assay
could be put to use. For the same family, family 1408, Figure 2.9 shows the
Indel-5 copy number assignment. It is a little more complicated and relies
more on the copy numbers found in the third generation, much like the
assignment of total haplotype copy number.
Figure 2.9 CEPH Family 1408. The diploid copy numbers of Indel-5 minor allele
(repeats containing the 5-bp sequences) are shown below the symbols in black. The
haplotype copy numbers for this allele are given in brackets next to the total
haplotype copy numbers in generation I and II.
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In family 1408, despite the high copy numbers it was easy to work out the
haplotypes mainly because of the variety of haplotypes they carry. In families
where parents share haplotype copy numbers, it becomes impossible to say
from segregation data only which haplotype carries the lone DEFA3 inherited
by the children when each parent has one copy, for example. In these cases,
further information could be obtained using linkage analysis and known
segregation patterns of linked markers.
2.8. SNP Association with Copy Number
Haplotypes
Some of the father-mother-child trios making up the first and second
generation of the CEPH families typed were part of the Phase I CEU HapMap
samples for whom phased SNP genotypes are available online
(www.hapmap.ncbi.nlm.nih.gov). Thus 14 such trios from 9 families were
available. The linkage disequilibrium block containing the DEFA1A3 repeats
extends from chromosome 8 coordinate 6,793,624 to coordinate 6,908,814
(UCSC Genome Browser assembly hg18). Excluding the children from the trios,
the haplotype copy numbers of DEFA1A3, Indel-5 minor allele and DEFA3
were combined with their SNP haplotypes. These were then sorted according
to the copy number of each of the three measures to look for SNP haplotypes
that tagged copy number lineages. Association of SNP haplotype with copy
number was evaluated using a chi-squared test, where the copy number
haplotypes were divided into two categories of various combinations. For
example, haplotypes that had no DEFA3 genes were compared against those
that had at least one, or haplotypes with 2 or 3 copies of DEFA1A3were
compared against those with 4, 5 or 6, and the frequency of the major allele
of the SNP was calculated in both categories. Starting with the hypothesis that
there would exist no difference in the SNP major allele frequencies between
the different copy number lineages, those SNPs that gave the lowest p-value
in each analysis were noted. Since the idea was then to test how well those
SNPs replicated this copy number-tagging ability in an independent set of
samples, the p-values were not corrected for multiple testing.
2.9. rs4300027 Genotyping Assay
SNP rs4300027 was found to give a low p-value for a chi-squared test of
independence between the major allele frequency in low-copy and high-copy
DEFA1A3 haplotypes. To test this association in an independent set of
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samples, namely the ECACC samples which had already been typed for copy
number, a SNP typing assay was devised. The SNP is a T to C transition. In the
C allele context, it makes the recognition site GAWTC for the restriction
enzyme TfiI. In the T allele context, this recognition site is lost. Primers were
designed around this SNP to include it and another non-variable TfiI site.
rs4300027-F: AGATACCATGCTTGGAGGAA
rs4300027-R: GGGTCTTGAATTCAAATGTCAG
PCR
36 cycles of:
95ȗC for 30 seconds
58.6ȗC for 30 seconds
70ȗC for 30 seconds
These primers give a product 1043 bp long. Digestion with TfiI gives 834 and
200 bp products in sequences with allele T, and 660, 200 and 174 bp products
in sequences with allele C.
chr8:6867808+6868850 1043bp
AGATACCATGCTTGGAGGAAgactaagcatcccacagggagaggaactgagcc
cacctgcaaggatgggctagagaacactgagcaaccagctttctaggaaaaaa
gaaaactctgatttgcaatgtttgtaaatttctgtggttaaaatgctcccagc
tatagacagtttaagaatcatcacacaaaaactcctccctcatgagctggcct
gatctgaccccagcacatcacagggtctcatccttcagctttctcagagtttc
cagctgagccaacaccacctgccacctgtgcacgagtgtcctggccctgaaat
tttcagatctcagcagaacctctcctcttatgcccgtggaaggatccaaaccc
caattgcaaatgtgtgagtgaagacgtgatcatgctgtttcaatccactactt
tctgtggtgtcttttcgcacagtcctagatgaacagaaggcacggtcttggtg
agaagttgaatgtgtgcattttttgtgtgtgtaaatctcagcctctctataat
attgttgaagtaggacagaaccctctcaccttatttccaaagtgtcacaaaga
gcccatcttaatggcagcgtggaattgtggactctttggagtgactgaagaac
ccccgtcacccattcttagtttaaattcttcctgttcagagcaggggtggtgt
gggagccaggtggagtgtcaacctctccccacagtgacagactcagaggaggc
cacgggacttgggggttggctggaacaacatgggaagaagtagggattttctc
caggagattagctacaaaagtcatagagagatgacgatgattcacatggttgt
cacctggggagagagcccaaagtaagttcaagagaaacaaagggaaaaaaaag
gtgaagacaacagtgtaactcatgctttgatttcttggatcaagcaattcctg
aagctagaattcctcctcaattccaagatataggagtcaaaatgttaacttag
cttgttgttggtttCTGACATTTGAATTCAAGACCC
rs4300027 is highlighted in green in the predicted PCR product sequence
above. The two TfiI sites are in bold and underlined. The first of these is thus
destroyed in sequences which have a T at this SNP position. The second of
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these, however, remains unchanged, and thus serves as a positive check of
enzyme digestion. The products from digestion were analyzed on a 1%
agarose gel via electrophoresis (Figure 2.10).
Figure 2.10 Agarose gel electrophoresis of TfiI digested products from the rs4300027
assay. Lanes 1 and 2 have T/C heterozygotes, lane 3 has CC homozygote, lane 4 has
TT homozygote, lane 5 is a PCR negative control and lane 6 is a DNA ladder. The
restriction digestion buffer has affected the electrophoretic mobility of the products,
so they migrate at a slower rate than the corresponding DNA markers.
2.10. DEFA4 Deletion Assay
From the PRT results for CEPH family 1346, it was observed for the maternal
grandfather, mother and four children that their inferred DEFA4-406 PRT copy
number was twice that measured from PRT MLT1A0. One simple explanation
of this discrepancy would be that they had only one copy of the DEFA4-406
PRT reference locus, the DEFA4 gene. The UCSC genome browser shows a
7169 bp deletion polymorphism (rs71926333) covering the DEFA4 gene, and
an overlapping 302 bp deletion polymorphism (rs72176738) at the telomeric
end in dbSNP build 130 (Figure 2.11).
1 2 3 4 5 6
500 bp
1 kb
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Figure 2.11 Snapshot of the UCSC genome browser showing the DEFA4 gene and the
7169 bp and 302 bp deletions, both represented as SNPs.
On searching the NCBI trace archives for sequences with the large and small
deletions, it was found that the 302 bp deletion (rs72176738) sequence was
ancestrally present in another location (purple bar in Figure 2.12). Also, the
302 bp deletion allele appears to be the ancestral state (so that the
polymorphism might be more correctly designated as an insertion) given the
frequency of its absence in the sequences on the NCBI trace archives. This
explained the occurrence of the large deletion due to the non-homologous
recombination between the perfectly matched 302 bp sequences at either
end. A three-primer PCR assay was designed that could check for the presence
of the 302 bp insertion and the 7169 bp deletion simultaneously (Figure 2.12).
The left primer (forward primer) is located outside the polymorphic region at
the telomeric side, the first right primer (reverse primer 1) within the 7169 bp
sequence and the second right primer (reverse primer 2) beyond the 302 bp
on the centromeric end. Three possible kinds of haplotypes can exist: one
which has no insertion or deletion, a second which has the insertion, and third
which has the deletion. In the first and second case, the forward and first
reverse primer will give products, but the sizes will be different depending
upon the presence or absence of the insertion. In case of the deletion, the
forward and second reverse primer will give products (designed to be of a
different size from the first two products).
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Figure 2.12 Scaled representation of the deletion and insertion (duplication)
polymorphism at the DEFA4 locus. Purple bar represents the original location
of the 302 bp, red bar the insertion of that sequence and the intervening
sequence is deleted along with 302 bp of sequence, some from the original
and some from the inserted 302 bp. Arrows denote the approximate position
of primers. The Forward and Revers1 primers will give products of sizes 526
bp and 828 bp from chromosomes without and with the insertion
respectively. The Forward and Reverse2 primers will give a product of size 720
bp from chromosomes with the 7 kb deletion.
Note that the forward and second reverse primer can always give a product,
but in the non-deleted state (A and B in Figure 2.12) it is almost 8 kb in size
and thus most probably not significantly amplified in the PCR nor is it in the
resolving range of the 1.5% agarose gel (Figure 2.13).
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Figure 2.13 Agarose gel electrophoresis of 7kbDEL PCR. Lane 1 is a DNA marker, lane 2
is a heterozygous carrier for the insertion, lanes 3 and 5 are heterozygous carriers of
the deletion and insertion, and lanes 4 and 6 are homozygous for the reference
sequence.
Primers
7kb DEL-F: CCTGATTCTACATTCTCTACCTA
7kb DEL-R1: GAATTGTAAGCTATCTCACATCT
7kb DEL-R2: CTTATGTATGTAAATGTTGTACGG
PCR
36 cycles of:
95°C for 30 seconds
52°C for 30 seconds
70°C for 30 seconds
2.11. PRT DEFTP1 and usDEL Assay
Primers for DEFTP1 PRT were designed that matched a sequence in the theta-
defensin pseudogene (DEFTP1) which is present in each full repeat, and a
1 2 3 4 5 6
500 bp
1kb
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paralogous sequence upstream of the first full repeat that has an annotated
alpha-defensin pseudogene (DEFA10P) which would act as a reference (see
Section 4.5). The usDEL assay was designed to genotype the apparent deletion
polymorphism in this paralogous sequence, upstream of the first full repeat
(see Section 4.5), which was also the reference site for PRT DEFTP1. Several
primer pairs failed to give a short product from carriers of the deletion, which
led to the hypothesis that it was a replacement rather than a deletion
polymorphism. Primers usDEL5-F and usDEL1-R were used to amplify across
this polymorphic region, and restriction enzyme digestion was used to
differentiate between products from the ancestral sequence (digests with
BstUI) and from the replacement-carrying sequence (digests with EcoRI).
Primers
DEFTP1 PRT-F: HEX-CTGCAGCTTCATCAGCTCT
DEFTP1 PRT-R: AAAACATGCCAGGATCCTC
usDEL5-F: TAGAGCTGGGACCATTTATG
usDEL1-R: GTTACGGTTAGAGCACAGGTAC
PCRs
1. DEFTP1 PRT
95ȗC for 3 minutes
26 cycles of:
95ȗC for 30 seconds
63ȗC for 30 seconds
70ȗC for 30 seconds
1 cycle of:
72ȗC for 30 minutes
2. usDEL5 PCR (using Phusion® Polymerase)
98ȗC for 30 seconds
37 cycles of:
98ȗC for 15 seconds
61ȗC for 30 seconds
72ȗC for 2 minutes 15 seconds
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1 cycle of:
72ȗC for 10 minutes
Restriction Enzyme Digestions
EcoRI: 5ʅl PCR product + 10ʅl Buffer and enzyme mix (1 Unit Enzyme per
reaction). Incubate at 37ȗC overnight.
BstUI: 5ʅl PCR product + 10ʅl Buffer and enzyme mix (1 Unit Enzyme per
reaction). Incubate at 60ȗC overnight.
ABI Capillary Electrophoresis of PRT DEFTP1
1ʅl PCR product + 10ʅl of HiDi® and ROX marker mix. Run voltage 1kV.
Injection time 30 seconds.
2.12. Upstream Sequence Replacement
Assay
A three-primer assay was designed for this polymorphism (see section 4.5).
The left primer (Repl1-F) was placed outside the telomeric end of the
replacement junction, selected to be specific to this site and not the full
repeat sequence, and two right primers were designed, one that matched the
reference upstream sequence (Repl1-orig-R) and a second that matched the
full repeat sequence (Repl1-repl-R).
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Figure 2.14 Agarose gel electrophoresis (1% agarose) of replacement assay PCR
products. Samples in lanes 2, 4 and 6 are heterozygous for the replacement
polymorphism, those in lanes 1, 5 and 7 have the reference sequence and the one in
lane 3 is homozygous for the replacement.
Primers
Repl1-F: AGCAGCAGATCCGGTATAATC
Repl1-orig-R: AGAGCCCAATAAATCTAACAGG
Repl1-repl-R: GTGAATCCAGAAAGAACGAGTC
PCR
95ȗC for 3 minutes
36 cycles of:
95ȗC for 30 seconds
60ȗC for 30 seconds
70ȗC for 30 seconds
1 2 3 4 5 6 7
500 bp
1 kb
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2.13. Protein Methods
Protein Extraction
As DEFA1, 2 and 3 are present in neutrophils, blood samples served as a
source for neutrophils from which proteins were extracted subsequently. The
protocol was adapted from a study by Linzmeier and Ganz (Linzmeier et al.,
2005).
Neutrophil Collection
Peripheral venous blood was drawn from healthy donors and collected in
EDTA-containing vacutainers (BD). At least 5 ml blood was taken.
Granulocytes were separated from other blood components by
centrifugation, using Lympholyte-poly ® by CEDARLANE® and following
manufacturers instructions. Lympholyte-poly ® is a separating medium that
contains dextran 500 and sodium metrizoate. Layering blood on an equal
volume of this medium and then centrifuging separates blood into red blood
cells, plasma, mononuclear cells and granulocytes. Of the granulocytes,
neutrophils make up about 95% of cells, and eosinophils and basophils make
up the rest. The neutrophils are not further purified as the presence of
eosinophils and basophils does not affect downstream assays, especially since
they are in small amounts as compared to neutrophils.
Protein Extraction
The separated neutrophils were suspended in normal saline (0.9% sodium
chloride). Their concentration was measured (cells per mL) using microscopy
with a haemocytometer slide. Volumes containing 5x10
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cells were taken in
1.5 mL eppendorf tubes, centrifuged to pellet the cells and supernatants were
discarded. These pellets were suspended in 100 µl acetic acid (5%), vortexed
and left shaking at 4 ȗC overnight. This suspension in acetic acid is the main
extraction step. After this step the suspensions were dried in a centrifuge
under vacuum. These dried extracts were then suspended in the appropriate
buffer depending upon the assay/procedure (see below).
Confirming Alpha Defensins in Protein Extracts
To check for the alpha defensin peptides, the neutrophil extracts were
analyzed on a SDS Polyacrylamide Gel Electrophoresis (PAGE) using a tris-
tricine buffer system. A discontinuous gel system consisting of a stacking gel
and an 18% resolving gel, and a Mini-PROTEAN II electrophoresis cell was
used. The dried extracts were suspended in protein loading buffer that
contained 2% SDS, 10% glycerol, 0.01% bromophenol blue in 0.06M Tris HCl
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(pH 6.8) and 0.8M DTT (Dithiothreitol). Prepared buffer pack was purchased
from Fermentas for use. DTT acts as a reducing agent to disrupt disulfide
bridges and bromophenol blue acts as a tracking dye during electrophoresis.
The samples were heated at 100 ȗC for 3 minutes before loading. The
electrophoresis time was about 1.75 hours, stopping when the dye had just
run off from the bottom of the gel. The voltage used was 80 V initially, until
the samples had entered the separating gel, and then increased to 160 V.
After electrophoresis, the gel was gently rinsed in tap water to wash off buffer
and then immersed in a fixing solution (40% methanol, 7% acetic acid) for one
hour. Then it was stained overnight in Coomassie Blue stain. The gel was next
de-stained in a de-staining solution (15% methanol, 10% acetic acid) for one
hour, and then in a fresh de-staining solution for another hour.
Gel and Buffer Recipes Used:
Gel Acrylamide
(ml)
4x Buffer
(ml)
TEMED
(µl)
40%
Ammonium
Persulphate
(µl)
Water
(ml)
Stacking 0.67 (A) 1 (a) 16 4 2.33
Resolving
(18%)
3.6 (B) 2 (b) 12 8 2.4
A= 30% acrylamide:bisacrylamide (37.5:1)
B= 40% acrylamide:bisacrylamide (19:1)
a= 4x Stacking buffer (0.5 M Tris HCl, pH 6.8, 0.4% SDS)
b= 4x Resolving buffer (1.5 M Tris HCl, pH 8.3, 0.4% SDS)
10x Anode Buffer: 1 M Tris-HCl, pH 8.9
10x Cathode Buffer: 3 M Tris, 1 M Tricine, 1% SDS, pH ~8.25
5 µl of a low range protein ladder (from Fermentas) was also run in each gel.
The expected size of the defensins band on the gel is 3.5 kDa. This band was
cut out and sent for peptide sequencing, which confirmed that it contained
the alpha defensins (see Section 6.3).
Acid Urea Gel Electrophoresis
To separate the three defensin peptides (or two, in case of DEFA3 absence)
extracted from neutrophils, acid-urea gel electrophoresis was employed. The
samples were same as for SDS-PAGE and ELISA (desiccated neutrophil
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extracts). The sample buffer, gel running buffer and gel recipes are given
below:
- Sample Buffer
o Acetic acid 0.06M
o Urea 4M
o Glycerol 20%
o Methyl Green 0.1%
- Electrophoresis Buffer
o Acetic acid 0.9M
- Stacking Gel
o Acrylamide* 7%
o Acetic acid 0.125M
o Urea 4M
o TEMED 0.5%
o APS** 0.2%
- Separating Gel
o Acrylamide* 12.5%
o Acetic acid 0.2M
o Urea 4M
o TEMED 0.33%
o APS** 0.2%
*Acrylamide used was a 37.5:1 acrylamide:bisacrylamide solution;
**APS=Ammonium persulphate (freshly prepared solution)
Pre-electrophoresis
After pouring the separating gel and allowing it to set, it was pre-
electrophoresed at a constant voltage of 200V (for 18x20 cm gels) for 12
hours. The buffer was then discarded and the stacking gel was poured with
the well-forming comb inserted at top.
Electrophoresis
Any unpolymerized solution was removed from the wells. Fresh
electrophoresis buffer was added. Samples were suspended in 15ʅl sample
buffer and applied to the wells. Electrophoresis was done at 300V for 5.5
hours.
Staining
The staining and de-staining of the gel was done following the same
procedure as for SDS-PAGE described earlier.
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Alpha Defensin Peptide Quantification by ELISA
For ELISA-based quantification of DEFA1, 2 and 3 peptides, an ELISA kit was
obtained from Hycult biotech ® that contained all components required. It
quantifies the three peptides together as the antibodies cannot discern
between the single amino acid change/absence that characterizes DEFA1, 2
and 3.
Sample Preparation for ELISA
The dried neutrophil extracts were suspended in the sample buffer provided
in the kit and diluted to give results within the range covered by the
standards.
Standards and Negative Controls Preparation for ELISA
The kit included purified DEFA1, 2 and 3 mix extracted from human
neutrophils in a desiccated form. This was dissolved in distilled water and 8
serial dilutions using sample buffer were made for each experiment, including
one blank. A set of 8 blanks mimicking the serial dilutions for the standards
were also included in each experiment. These blanks had pure distilled water
instead of the dissolved standard peptides.
Principle of ELISA
This ELISA worked on what is called the sandwich method. The standards,
blanks and samples were applied to the wells which were pre-coated with the
antibodies. After washing off unbound proteins, a secondary antibody to the
defensin peptides was applied, thus forming a sandwich with a layer of alpha
defensin peptides between layers of antibodies. These secondary antibodies
had biotin attached to them. After washing off unbound antibodies,
streptavidin-peroxidase conjugate was applied to the wells. After washing off
unbound streptavidin-peroxidase conjugate, a substrate for the enzyme
peroxidase is applied. This substrate is 3, 3, 5, 5-tetramethylbenzidine (TMB)
which is colourless. When peroxidase acts upon it, it is converted to a blue
product. To stop the reaction, acid is added to the wells, which also causes the
blue product to change to yellow. The absorbance of this product is measured
at 450 nm. The higher the absorbance, the more biotin-conjugate antibody is
present, corresponding to a larger amount of defensins in the sample applied
to the well.
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2.14. Samples, General Reagents and
Procedures
PRT Standard/Reference Samples
These samples are from the UK population extracted from whole blood using
a standard phenol/chloroform method adapted from the Nucleon DNA
extraction kit (Aldred et al., 2005).
ECACC Samples
ECACC (European Collection of Cell Cultures) DNA samples are random UK
Caucasian control samples obtained from the Health Protection Agency
(www.hpacultures.org.uk). ECACC panel 1 and 2 were used. These DNA
samples are extracted from cell lines derived by Epstein Barr Virus
transformation of peripheral blood lymphocytes.
HapMap Samples
The 90 HapMap CEPH (CEU) DNA samples are from the U.S. population with
Northern and Western European ancestry, that were collected by the Centre
dEtude du Polymorphisme Humain (CEPH). The 90 HapMap Yoruban (YRI)
samples come from the people of Ibadan, Nigeria. CEPH and Yoruban HapMap
samples are made up of 30 trios of mother, father and child. Of the 90
HapMap Asian samples 45 come from unrelated Han Chinese from Beijing and
the other 45 from unrelated Japanese from Tokyo. All HapMap DNA samples
are part of the International HapMap project (Gibbs et al., 2003), and have
been obtained from the Coriell Institute (http://ccr.coriell.org). These DNA
samples are extracted from cell lines derived by Epstein Barr Virus
transformation of peripheral blood lymphocytes.
CEPH Families
Seventeen three generation CEPH families of European origin were used in
the segregation analysis. Five of these families had both sets of grandparents
and both parents (two trios) and four of these families had just one set of
grandparents and one parent (one trio) also represented in the HapMap CEPH
samples described above. These DNA samples have also been obtained from
the Coriell Institute (http://ccr.coriell.org).
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Cystic Fibrosis Samples
These DNA samples were kindly provided by Ed Hollox, and had been
extracted from peripheral blood using QIAamp DNA Blood Midi kit (Qiagen)
(Hollox et al., 2005).
DNA Extraction fromMononuclear Cells
Mononuclear cells were collected from the separated blood (Section 0).
Genomic DNA was extracted from these cells using GenElute
TM
Mammalian
Genome DNA Kit (Sigma) as per manufacturers recommendations.
Standard PCR Mix
Quantities per 10µl reaction:
10x LD Buffer 1.0µl
Primers (10µM) 0.5µl
Taq Polymerase 0.1µl
Water 7.4µl
DNA (10ng/µl) 0.5µl
10x LD Buffer:
- Tris-HCl pH 8.8 500mM
- Ammonium sulphate 125mM
- MgCl2 14mM
- 2-mercaptoethanol 75mM
- dNTPs 2mM (each)
- BSA 1.25mg/ml
Phusion® Polymerase PCR Mix
Quantities per 10µl reaction as recommended by manufacturer (New England
BioLabs):
5x Buffer (GC buffer)*2.0µl
10mM dNTPs 0.2µl
Primers (10µM) 0.5µl
Phusion Polymerase* 0.1µl
Water 5.7µl
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DNA 1.0µl
*Buffer and enzyme from NEB
Agarose Gel Electrophoresis
Depending upon the size of DNA molecules to be separated, agarose gels of
varying concentrations were used (0.8 to 3.5%). According to desired gel
concentration, the required amount of agarose was weighed and dissolved in
a corresponding volume of 0.5x TBE buffer containing 0.5µg/ml Ethidium
Bromide. Before applying samples to the gel, they were mixed with 2µl of
loading buffer (0.5x TBE, 8% sucrose and 0.004% bromophenol blue) per 10µl
of sample volume. Gel running buffer was the same as gel preparing buffer
and gels were run using a constant voltage of 140V until the bromophenol
blue had reached the end of the gel. 1µl of either the 100bp or 1kb DNA
ladder (500µg/ml from NEB) mixed with 7µl of water and 2µl of loading buffer
was also run in each experiment. After electrophoresis, the separated DNA
molecules in the gel were visualized under UV light.
Primer Design
Primers for PRT MLT1A0 and DefHae3 assay were designed by Prof. John
Armour and Patricia Aldred (Aldred et al., 2005) respectively. All other primers
were manually chosen using sequence information from the UCSC genome
browsers human genome assembly hg18 and expected products were
obtained using the in-silico PCR function; predicted PCR products were further
checked by BLAT searching against the human genome assembly to look for
possible non-specific products; Tms were calculated using primer3
(http://frodo.wi.mit.edu/primer3), and trace archives and dbSNP from the
NCBI website (http://www.ncbi.nlm.nih.gov) were used to check for sequence
variants in the primer sequences. For any given PCR, those primer-pairs were
chosen which had the most similar Tms.
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3. DEFA1A3 COPY NUMBERS
The primary aim was to apply the copy number measuring assays to European
samples using calibrators of known copy numbers, which were also used to
assess the accuracy of the assays. This chapter presents the results from the
four copy number measuring assays (see Sections 2.1 and 2.2). The assays
between them measure not only the total DEFA1A3 copy number, but also
the copy number of the full repeats (from PRT MLT1A0), copy number ratio of
the DEFA1 and DEFA3 genes (from DefHae3 assay) and copy number ratio of
the two Indel-5 alleles. It is assumed that each repeat, full and partial, carries
one copy of the DEFA1A3 locus, and that the DEFA1A3 locus does not exist
elsewhere independently. It is also assumed that each chromosome 8 carries
exactly one partial repeat and a variable number of full repeats. This means
that measures from PRT DEFA4-406, which amplifies across the gene itself,
should be two more than the measures from PRT MLT1A0, which is specific
for the full repeats. The ratios from both Indel-5 and DefHae3 assays should
correspond to total DEFA1A3 copy numbers, because the Indel-5 PCR
amplifies across a sequence common to both full and partial repeats, and the
DefHae3 assay amplifies a sequence from the gene. The total copy numbers
were arrived at using the MLCN program (see Section 2.4). The DEFA3 and
Indel-
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Figure 3.1 Scaled diagram of the full and partial repeats showing the position of the four assays with
respect to the DEFA1A3 locus. Note that the test sequence amplified in PRT MLT1A0 is only present in the
full repeat.
3.1. Total Measured Copy Numbers
Samples from three populations were typed for DEFA1A3 copy number using
the PRTs and allele ratio assays: European, African (Yorubans from Ibadan,
Nigeria) and Asian (Han Chinese and Japanese). From the results of these
measurements and study of haplotypes, it is clear that the substructure of this
locus is different enough between these populations to treat them as three
distinct groups rather than group them together. Also, the quality of the
assays in terms of agreement between them for any given sample varied
between the three groups. This could be due to any one or a combination of
the following reasons: a) sequence divergence at this locus between the
populations that affects one or more of the assays, and the use of European
samples as calibrators, b) differences in DNA preparation that affect one or
more of the assays. The first of these issues could be overcome by using
samples from the same population as calibrators if the sequence divergence
within the population is not significant or if it does not affect the PCR assays
concerned. Similarly the second possible cause of error could be overcome by
using calibrating samples prepared using identical procedures, and such that
the procedures are consistent in the quality of DNA they produce. In this
section results from measurements using the standard European calibrators
are presented.
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Europeans
284 DNA samples from unrelated individuals (99 CEPH and 185 ECACC
samples) were typed with the four assays. One sample carried a rare deletion
of the DEFA4 gene, which acts as the reference locus in PRT DEFA4-406, but
no other variation affecting any other assay in these samples was determined.
The deletion in DEFA4was determined by a three-primer assay (see Section
2.10) after observing the double or higher ratio of test to reference from this
PRT compared to the MLT1A0 PRT in not just one sample, but also in the
progeny of the sample that had also been typed. Some of the samples were
tested for a deletion in the DEFA1A3 gene itself on suspicion of getting lower
than expected copy numbers from the DEFA4-406 PRT but no deletion was
found (see Section 2.5). There is a 580 bp deletion catalogued as rs71776817
on the SNP database. Similar to Aldred et als MAPH measurements, the copy
numbers for DEFA1A3 in Europeans ranged from 3 to 11. The frequency and
range are depicted in Figure 3.2. Note that this figure does not include the 3-
copy individual as it is the child of two samples already included. However, it
signifies the presence of a one-copy haplotype in one of the samples.
Figure 3.2 The range and frequency of measured copy numbers in 284 unrelated
Europeans.
Asians
90 unrelated DNA samples from the HapMap Asian sample set were typed
with the four assays. 45 were of Japanese origin and 45 of Han Chinese. The
distribution of copy numbers is shown in Figure 3.3. When the two populations
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are separated, it is seen that the copy number distribution is different
between them (t-test p-value= 1.4x10
-14
) (Figure 3.4).
Figure 3.3 Copy number distribution of DEFA1A3 in 90 unrelated Asian samples
63
Figure 3.4 Copy number distribution varies between the 45 Han Chinese and 45
Japanese samples typed.
Africans
60 unrelated Africans from the HapMap Yoruban collection were typed with
the four assays. The range and frequency of the measured copy numbers is
given below (Figure 3.5).
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Figure 3.5 Copy number distribution in 60 unrelated Africans.
3.2. Copy Number Measurement Quality
Calibrating the PRTs
As mentioned in the Methods section of this thesis, the eight samples used to
calibrate the PRTs were of known copy numbers as determined by RFLP,
pulsed-field gel electrophoresis and Southern blotting (Aldred et al., 2005).
These methods left no doubt about the accuracy of their copy number
determination. Thus the calibration of the PRTs was set on firm foundations.
Not only do these standard samples calibrate other tested samples, but they
also act as a test of the accuracy of the PRTs. Repeated typing of these
samples with the PRT assays and plotting the ratios obtained against their
known copy numbers shows the accuracy and precision of these assays (Figure
3.6 and Figure 3.7). Of the eight calibrating samples, there are four with 8
copies, and one of each with 5, 6, 7 and 9 copies. Note that the ratios from
PRT MLT1A0 (Figure 3.6) are lower than those from PRT DEFA4-406 (Figure 3.7).
This is probably due to the fact that PRT MLT1A0 measures two copies less
than the total, whereas PRT DEFA4-406 measures all copies. The actual ratio
from a PRT is not important as long as the ratios from a given copy number
are consistent and distinct from ratios from other copy numbers, such that
plotting the ratios against the total DEFA1A3 copy numbers should give a
linear correlation. The ratios from PRT MLT1A0 are actually an average of the
ratios from two tests: one with FAM-labelled primers and one with NED-
labelled primers (see Section 2.1).
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Figure 3.6 PRT MLT1A0 ratios (averaged for both dyes) of the calibrating samples
plotted against their known total copy numbers (not copy numbers of full repeats
only). Each sample has been tested four times, giving 32 data points.
Figure 3.7 PRT DEFA4-406 ratios of the calibrating samples plotted against their
known copy numbers. Each samples has been tested four times, giving 32 data
points.
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Of the four 8-copy calibrators, there is no single one that consistently gives
the higher than average ratios in both PRTs. However, it is one particular one
that consistently gives lower than average ratios in both PRTs. The error in
copy number calling increases as copy numbers increase, which is expected.
Since PRT MLT1A0 measures only the full repeats, it is measuring 2 copies less
than the other PRT for any given sample. Also, PRT MLT1A0 had the
advantage of being performed twice per sample, in the form of using two
separately labelled primers, as opposed to PRT DEFA4-406 which was only
performed once per sample. Despite this, the standard deviation for PRT
MLT1A0 is equal to or higher than PRT DEFA4-406 for the same samples
(Figure 3.8).
Figure 3.8 Standard deviations of the PRT-measured copy numbers of the calibrating
samples plotted against their copy numbers.
A possible reason for this could be the nature of the sequences used in the
PRTs. For PRT MLT1A0 this is a dispersed repeat sequence and thus has
several copies of similar sequences around the genome. Although the primers
are specific to the test and reference loci and do not match exactly anywhere
else on the reference genome browser, non-specific amplification remains a
possibility. Figure 3.9 shows the best-matched sequences in the genome to
the test (chr 8) and reference (chr 1) loci of PRT MLT1A0 from a BLAT search.
For PRT DEFA4-406 the sequence selected is an alpha defensin gene-specific
sequence and only shared between the DEFA1A3 and DEFA4 genes.
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Figure 3.9 Alignment of the best-matched sequences to the PRT MLT1A0 test locus
(chr8) and reference locus (chr1). Primer sequences are in red.
Agreement between the PRT measurements
Agreement between the PRT measurements is evidence of accuracy for both
the assays. PRT MLT1A0 measures a sequence in the full repeat outside of the
DEFA1A3 locus and PRT DEFA4-406 measures across the gene itself. However,
since both PRTs are calibrated against total genomic DEFA1A3 copy numbers,
they should give the same measurement for each sample, unless there is a
deviation from the assumed structure of this CNV. As mentioned earlier in this
chapter, agreement between the results of both PRTs varies between the
three different population samples typed. The highest agreement is seen in
the European samples (Figure 3.10), in the form of data point clusters on the
graph. This clustering breaks down in the case of Asian and African samples
(Figure 3.11 and Figure 3.12). In the case of the discordant African samples,
PRT DEFA4-406 usually gives a higher copy number measurement than PRT
MLT1A0. Some almost twice as high but not quite. However, none of these
samples carried a deletion of the reference sequence as tested by the DEFA4
Deletion Assay (see Section 2.10). This decrease in agreement means that the
confidence in assigning copy numbers even after taking into account the allele
ratio assays, especially in the case of African samples, decreased.
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Figure 3.10 Clusters of copy numbers observed when the unrounded copy numbers
measured from both PRTs are plotted against each other. The correlation between
the two is R
2
=0.8433 (from MS Excel). These are results from 250 European samples
(HapMap CEPH and ECACC panels).
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Figure 3.11 PRT-measured copy numbers of 91 HapMap Asian samples plotted against
each other (correlation R
2
=0.8981 from MS Excel).
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Figure 3.12 PRT-measured copy numbers of 89 HapMap African samples plotted
against each other (correlation R
2
=0.7175 from MS Excel).
PRT Measurement Error Distribution
Since we assume that the copy numbers of DEFA1A3 that are measured by
the PRTs are whole numbers, the measurements should centre on whole
numbers and the errors should have a normal distribution if they are random
rather than biased in one direction. In the histograms below are the error
distributions of copy numbers from both PRTs as compared to a fitted normal
distribution, using the MLCN-program generated copy numbers as references.
Thus the assigned copy numbers take into account not just both the PRTs but
also the ratios from Indel-5 and DefHae3 assays.
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Figure 3.13 Bars represent the frequency of PRT MLT1A0-measured copy numbers
error around a mean of 0.96 (from dividing PRT-measured copy numbers by MLCN),
and the black dots represent their expected normal frequency distribution with the
same mean and standard deviation.
The error for each sample is calculated by dividing its PRT-derived copy
number values (unrounded) with its MLCN. These were binned into intervals
of 0.01 and their histograms plotted as red bars in the figures (Figure 3.13 and
Figure 3.14). Using the mean and standard deviation of these values, the
number of samples to expect within each bin is calculated as the product of
the normal probability distribution and total number of samples. These are
plotted as the black dots in the figures.
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Figure 3.14 Bars represent the frequency of PRT DEFA4-406-measured copy numbers
error around a mean of 0.99 (from dividing PRT-measured copy numbers by MLCN),
and the black dots represent their expected frequency distribution.
These error distribution histograms compared with expected normal
distributions are thus a visual analysis of whether there is any skew in the
error of both PRTs. The QQ (Quantile Quantile) plots below are plotted to
demonstrate the same, i.e. there is no significant skew in error and it follows a
normal distribution for both PRTs. QQ plots are a graphical technique to check
for normality, by plotting the quantiles of test sample against theoretical
quantiles of a normally distributed population with the same mean. In the QQ
plots below the actual error of the PRT measurement is plotted against
normal theoretical values generated given the number of test samples. The
error is calculated for each sample, by subtracting the PRT-measured
unrounded copy numbers from the MLCN of the sample. Thus, the mean of
this distribution is zero, and therefore the theoretical values were calculated
in MS Excel as inverse of a standard normal probability distribution.
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Figure 3.15QQ plot of PRT MLT1A0-measured copy numbers error (from subtracting
PRT-measured copy numbers from MLCN). Theoretical values are plotted on the x-
axis and copy number errors on the y-axis.
Figure 3.16QQ plot of PRT DEFA4-406-measured copy numbers error (from
subtracting PRT-measured copy numbers from MLCN). Theoretical values are plotted
on the x-axis and copy number errors on the y-axis.
The outlier in the PRT DEFA4-406 Q-Q plot is a one-off case of higher than the
average error. While all other assays for this sample agree on a copy number
of 9 (PRT MLT1A0 unrounded copy number= 8.9, Indel-5 ratio= 8.2, DefHae3
corrected ratio= 3.5), PRT DEFA4-406 gives an unrounded copy number of
74
12.7. On looking up the ABI trace for this sample, it seems that the peak from
the reference product does not have the uniform shape of a good quality peak
(Figure 3.17). It may be that the higher than expected ratio for this sample
resulted from an error in quantifying the reference product by the ABI. The
sample was not re-tested.
Figure 3.17 ABI trace for PRT DEFA4-406 of a sample giving a higher than expected
ratio. The peak from the reference product looks suspect.
Agreement with Microarray data
This was the only case where PRT-based copy number measurements could
be compared to measurements from another method performed in another
laboratory. Besides the one HapMap CEPH sample included in the samples
typed by the PRTs that was used as the reference for this array- CGH
experiment, 9 HapMap CEPH and 9 HapMap YRI samples also typed by the
PRTs were test samples in the aCGH (Conrad et al., 2010). The reference
sample was measured by the PRTs to have a copy number of 7, which meant
all samples that had 7 copies would give a log2 ratio of 0 in the array CGH.
Samples with copy numbers higher than 7 should give ratios larger than 0, and
those with lower than 7 should give negative values.
Although it is a small number of samples but nevertheless an agreement
between the two results as seen in the graphs below gives an independent
source of confidence in the PRT measurements.
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Figure 3.18ML CN plotted against log2 ratios from the microarray for 9 HapMap CEPH
samples. The chromosome 8 coordinates mentioned in the y-axis label are from
hg18.
Figure 3.19ML CN plotted against log2 ratios from the microarray for 9 HapMap YRI
samples. The chromosome 8 coordinates mentioned in the y-axis label are from
hg18.
The PRT-based ML CN and array-CGH data can also be compared via
calculating the expected binary logarithms of the aCGH ratios for each copy
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number. The table below shows the obtained data matches the expected
values very well.
Table 3.1 Comparison of log2 ratios of the DEFA1A3 repeat region from array-CGH with
expected log2 ratios that have been calculated based on DEFA1A3 copy numbers measured by
the PRT-based assays
ML CN Expected
log2ratios
Obtained log2ratios from array-CGH (averaged
in case of more than one sample)
5 -0.485 -0.47311
6 -0.222 -0.2688
7 0 -0.02028
8 0.193 0.117915
9 0.362 0.374081
13 0.893 0.88143
3.3. DefHae3 and Indel-5 Assay
The ratios obtained from these assays are useful for two purposes. Firstly,
they corroborate the total copy numbers measured from the PRTs. Before
using DefHae3 ratios, they are corrected to account for the bias caused by
heteroduplex formation (see Section 2.2). To illustrate the usefulness of these
ratios, consider obtaining a corrected ratio of 2.5 from a sample that has PRT-
measured copy numbers between 7 and 8. This ratio would support a copy
number of 7 over 8, because 2.5 can result from a ratio of 5 copies to 2 which
total 7, and cannot result from a total of 8 copies. Secondly, the number of
copies containing the DEFA3 gene, the DEFA1 gene, the undeleted and the
deleted versions of the Indel-5 polymorphism are simultaneously determined.
The table below lists ratios from these assays alongside the PRT-measured
copy numbers for seven ECACC samples, and the interpretation of those ratios
in terms of number of copies of each allele.
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Table 3.2 PRT-measured copy numbers of seven ECACC samples and the interpretation of
their Indel-5 and DefHae3 ratios based on these measurements. Note that the copy numbers
measured from PRTMLT1A0 have been calibrated to include the two partial repeats for each
sample, and are thus copy numbers of total DEFA1A3, similar to the measurement from PRT
DEFA4-406.
S
a
m
p
le
ID
PRT
MLT1A0
unrounded
CN
PRT DEFA4-
406
unrounded
CN
Indel-5 ratio
(deleted to undeleted)
DefHae3 ratio
(DEFA1 to DEFA3)
measured interpreted measured corrected interpreted
10 3.50 3.99 0 4 to 0 0.91 1.05 2 to 2
11 6.98 6.94 2.51 5 to 2 4.91 5.65 6 to 1
12 7.03 8.07 3.04 6 to 2 2.41 2.77 6 to 2
14 4.73 4.96 3.89 4 to 1 1.33 1.53 3 to 2
15 5.62 5.88 1.03 3 to 3 4.31 4.96 5 to 1
16 9.61 9.36 4.03 8 to 2 3.48 4.01 8 to 2
44 8.57 9.03 3.39 7 to 2 7.36 8.47 8 to 1
DEFA3 Absence
It is known that DEFA3 is absent in about 10% percent of the European
population (Aldred et al., 2005) and in about 10% and 37% of Asian (Chinese
and Japanese) and African populations respectively (Ballana et al., 2007).
Using the DefHae3 ratios and the PRT-based total copy numbers, DEFA3 gene
copy numbers were determined for CEPH, ECACC, HapMap CHB/JPT and
HapMap YRI samples, and similar frequencies of DEFA3 gene absence were
observed.
Population Total unrelated samples
typed
DEFA3 absent in
Europeans 246 30 (12.1%)
Asians (CHB/JPT) 86 8 (9.3%)
Africans (YRI) 58 26 (44.8%)
Indel-5 minor allele copy number
As is true of total copy number, and DEFA3 absence, the copy numbers of
DEFA1A3 repeats based on this allele also show a difference in distribution
between the European and non-European populations (p-value=10
-4
).
European samples have up to 6 copies of the minor allele whereas non-
Europeans only show up to 4 copies (Figure 3.20). No difference between
Asian and African samples was observed (p-value=0.76).
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Figure 3.20 Copy number frequency of the Indel-5 minor allele in the three
populations
Interestingly, a relationship between the Indel-5 minor allele and DEFA3 gene
copy number was observed in the European population. Samples with zero
copies of DEFA3 tended to have higher copy numbers of Indel-5 minor allele
and vice versa (Figure 3.21).
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Figure 3.21 Frequency of DEFA3 copy numbers for each copy number category of
Indel-5 minor allele. Samples with high copies of the Indel-5 minor allele have a
higher frequency of DEFA3 absence. There is no overlap of absence of both the minor
allele and DEFA3 gene. The DEFA3 CN=2 data have been deliberately omitted for a
clearer picture.
The Asian and African samples do not show this relationship between Indel5
and DEFA3 copy numbers.
3.4. Conclusion and Discussion
As has been mentioned in the introductory chapter, absence of reliable typing
systems for a complex and multiallelic CNV like the alpha defensin CNV has
left a gap in studying and understanding such loci in the genome. This chapter
has shown how the combination of four PCR-based assays (PRT MLT1A0, PRT
DEFA4-406, Indel-5, and DefHae3) can be used as a reliable and informative
CNV measuring system for DEFA1A3. Copy numbers measured range from 3
to 11 in Europeans and 4 to 16 in Africans and Asians (Chinese and Japanese).
The accuracy of the CNV measuring system has been shown by correlation
between PRT ratios and known copy numbers of calibrators, agreement
between the four assays, normal error distribution for the PRT-based copy
numbers and correlation of measured copy numbers with an external,
independent study. Since the PRT is in itself a relative measure, providing
ratios instead of whole copy numbers, the importance of reliable calibrators
cannot be overstated. For the DEFA1A3measuring system, the copy number
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of the calibrators has been determined by pulsed-field gel electrophoresis
(Aldred et al., 2005), leaving no doubt of their correctness. Also, importantly,
prior to their use for calibrating other samples, they provide a means of
measuring the accuracy of the PRTs (Figure 3.6 and Figure 3.7). All four assays
are PCR-based and require capillary electrophoresis for analysis of products.
The PCRs on average take 2 hours and electrophoresis takes 45 minutes per
16 samples. Thus, it is a high-throughput system to perform. The designing
and optimizing of the assays is the slowest stage of the process, as is true for
any new study.
The lower level of agreement between the assays for the non-European,
especially African, samples could be due to differences in the quality of DNA,
or could result from SNPs in those populations that are not represented in the
Europeans. Now, with the availability of genomic sequence data from large-
scale sequencing projects, most notable being the 1000 Genomes project,
even relatively low frequency sequence variants can be checked in several
populations. On checking the latest SNP databases that include data from the
1000 Genomes project, two SNPs were found in the forward primer-binding
sequence of PRT DEFA4-406 reference site. One, rs7816407, has a minor allele
frequency of 0.009, but no information on which population it was found in. It
is also reported by another sequencing project, where they found it in an
African (Northern Kalahari) sample. The other, rs2741681, has a minor allele
frequency of 0.025 in the complete 1000 Genomes data, but was found in the
pilot scale African (YRI) sample (59 individuals) to have a minor allele
frequency of 0.102. This SNP is a C to G transversion at the 9
th
base of the
forward primer from the 3 end. If this SNP is present at a MAF of 0.102 in
Africans, it should be found in 18.5% of African individuals, and if it affects
primer binding, it should result in a higher than expected measure of copy
number from PRT DEFA4-406, which is about what has been observed in the
tested African samples (Figure 3.12). However, no sample was checked for
this SNP, and it remains uncertain what causes the discordance in the African
samples. At least in Europeans, this measurement system remains robust and
applicable, and can also be used for delineating haplotype copy numbers by
typing three-generation families as has been done in the next part of this
study (Chapter 4).
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4. DEFA1A3 HAPLOTYPES
In this part of the study the aim was to obtain copy number haplotypes for
DEFA1A3, obtain mutation rates (copy number changing mutations) and
combine haploid copy numbers with surrounding SNP genotypes by using the
copy number measuring assays to obtain diploid copy numbers in three-
generation families, which had members included in the HapMap database.
4.1. Segregation Analysis of CEPH
families
To obtain haplotype copy numbers for the DEFA1A3 locus, DNA samples of
individuals from 17 three-generation CEPH families of European origin were
typed with the two PRTs (MLT1A0 and DEFA4-406) and the two allele ratio
assays (Indel-5 and DefHae3). These DNA samples were obtained from the
Coriell Institute for Medical Research and their details are provided in section
2.14. The details of the families are given in the table below. Of the 64
individuals of the first generation, 28 are also part of the CEU HapMap
samples. They are highlighted in red.
Table 4.1 Table detailing total number of individuals and number of individuals in each
generation of the 17 CEPH families typed. Family ID is also included.
Family Number Total Individuals Generation
1
st
2
nd
3
rd
1362 17 4 2 11
1408 14 4 2 8
1341 13 4 2 7
1350 13 4 2 7
1346 14 2+2 2 8
1334 13 4 2 7
1375 12 2+1 2 7
1416 16 2+2 2 10
1345 13 2+2 2 7
1332 16 4 2 9
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Family Number Total Individuals Generation
1
st
2
nd
3
rd
104 14 2 2 10
66 11 3 2 5
1333 14 4 2 8
884 18 4 2 11
1331 17 4 2 10
12 13 4 2 7
1424 14 4 2 7
These families are useful for segregation analysis because of the large number
of individuals in the third generation, which allows the observation of all four
possible combinations of haplotypes from the parents (2
nd
generation
individuals) and because of the availability of segregation information from
genetic markers across their genomes (www.cephb.fr). For this study,
segregation information for 44 markers around the DEFA1A3 locus was used.
Of these, 20 were on the telomeric side of the locus and 24 were on the
centromeric side. The closest marker on the telomeric side is at the
coordinate position of 6,741,958 which is about a distance of 73 kb and on the
centromeric side is at the position 8,805,729 which is about 1.9 Mb from the
locus. This segregation data tells us which two grandparents (1st generation
individuals) contributed to each genetic locus typed in the third generation.
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Figure 4.1 A shows family 1408, in which haplotype copy numbers for all individuals
were easily inferred from their measured diploid copy numbers. This was because
there was only one possible arrangement of alleles. The red coloured haplotypes in
the grandparents are the untransmitted ones. B describes the symbols and numbers
used in A.
For any given family, to obtain haplotype copy numbers of DEFA1A3, DEFA1,
DEFA3, and Indel-5 alleles, first the diploid copy numbers from the two PRT
measurements and allele ratio assays for all members were assigned
manually. These were then used to infer the possible haplotype combinations
in each individual. For some families no further information was needed to
assign all haplotypes unambiguously. A good example of this scenario is family
1408 (Figure 4.1). The female in the second generation (mother) was inferred
to have haplotypes with copy numbers 6 and 2 from her own, the fathers and
their childrens diploid copy numbers. Given that the maternal grandmother
B
A
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has a diploid copy number of 4, she cannot have passed on a 6-copy
haplotype to her daughter and so it becomes clear that the 2-copy haplotype
came from the maternal grandmother, and the 6-copy haplotype came from
the maternal grandfather. The other two haplotypes from these grandparents
were then inferred given their diploid measurements. In the case of the father
in this family, the haplotype copy numbers inferred were 4 and 5. Either of
the paternal grandparents could have a 4 or 5-copy haplotype as their diploid
copy numbers are 8 and 7. However, the 4-copy haplotype has three copies of
the indel-5 minor allele which is greater than the diploid indel-5 minor allele
copy number in the paternal grandmother (only one) but fits in with the
paternal grandfathers indel-5 minor allele diploid copy number of 4. Thus the
4-copy haplotype is assigned to the paternal grandfather and the 5-copy
haplotype is assigned to the paternal grandmother. This segregation of
haplotypes was then checked by comparing to the segregation information
from linked markers in the CEPH genotype database and was found to agree
with it.
For some families, it was not possible to unambiguously assign haplotypes to
the grandparents on the basis of measured copy numbers alone. For example,
in family 1350 the haplotypes inferred for the father are both 5 copy with one
copy of DEFA3 (Figure 4.2). This allows easy assignment of total and DEFA3
copy number haplotypes in the paternal grandparents but the indel-5 minor
allele haplotype copy numbers are different and in a manner that both
haplotypes are compatible with both paternal grandparent diploid copy
numbers. A similar situation for the mother and maternal grandparents is also
seen in this family, where both haplotype copy numbers (4 and 5) are
compatible with both grandparents and DEFA3 and indel-5 minor allele copy
numbers are also not informative. To illustrate this limitation, the
grandparents haplotypes have been left blank in part A of the figure. Using
the segregation information of surrounding genetic markers from the CEPH
genotype database, it was learnt which child had inherited from which two
grandparents, and from this information the haplotypes could be assigned in
the first generation (Figure 4.2 B).
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Figure 4.2 CEPH family 1350, where haplotypes for the second generation have been
inferred given the diploid copy numbers measured in generation 2 and 3. A shows
that from this information alone which haplotype comes from which grandparent
cannot be inferred. All combinations are possible. B shows the assignment of
haplotypes based on segregation information of surrounding genetic markers which
tells us for each child which two grandparents contributed to his/her genotype.
While the segregation information from the CEPH database is necessary to
assign haplotypes in some families, they are equally necessary in others to
check the completely independent haplotype assignment. That is because
given the possible errors in copy number measurements, the possibility of
A
B
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haplotype rearrangements during gamete formation, and not knowing the
true extent of structural complexity and the rate of copy number changes at
this locus, incorrect assignments of haplotype copy numbers are possible.
4.2. Copy Number Haplotypes in
Europeans
For each family, the number of unique haplotypes for DEFA1A3 (or any other
locus) is twice the number of individuals in the first generation. From the 17
families studied, the total number of first generation individuals typed is 64
which can give information for 128 DEFA1A3 haplotypes. However, 4 of these
64 samples did not give analyzable PCR products from both PRTs and at least
one allele ratio assay and were thus only partially informative. For these 4
individuals only one haplotype could be inferred, the one they had passed on
to their child in the second generation, and the other haplotype could not be
inferred because their total copy numbers were not measured. Another first
generation individual, from family 1346, had results from both PRTs and allele
ratio assays, but he had a DEFA4 deletion which rendered one PRT useless;
furthermore, a high total copy number from the other PRT was observed
which could not be assigned with great confidence and therefore a copy
number was not inferred for his non-transmitted haplotype. In all, 123
haplotype copy numbers were obtained from 64 individuals (both haplotypes
for 59 individuals and only one haplotype from 5 individuals). The total
haplotype copy numbers ranged from 1 to 7 in these 123 samples (Figure 4.3).
Given the diploid copy number range measured in Europeans (3 to 11), this is
an expected result with the exception of observing two 7-copy haplotypes.
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Figure 4.3 Total haplotype copy numbers found for DEFA1A3 range from 1 to 7 in
Europeans.
It may not be intuitively obvious why copy number haplotypes should follow
this distribution (Figure 4.3) given the measured diploid copy numbers, with
4-copy haplotypes being less frequent than 3 and 5-copy ones. These are in
total 123 and should be a good sample size to represent the population
average. On calculating the expected frequency of each diploid copy number
class from these haplotype frequencies, it can be shown that in fact this
distribution matches with measured diploid copy numbers in Europeans. The
table below shows these frequencies. Expected frequencies were calculated
using the formula (a+b+c+d+e)
2
, where a to e are frequencies of 2-copy to
6-copy haplotypes. 1 and 7-copy haplotypes were ignored.
Table 4.2 Observed and expected frequencies of each diploid copy number class for European
samples
Diploid Copy Number Expected Frequency Observed Frequency
4 0.054 0.058
5 0.136 0.093
6 0.162 0.19
7 0.229 0.229
8 0.204 0.225
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Diploid Copy Number Expected Frequency Observed Frequency
9 0.109 0.108
10 0.088 0.081
11 0.014 0.011
The haplotype copy numbers for DEFA3 and the indel-5 minor allele ranged
from 0 to 2 and 0 to 3 respectively. These too are expected given the diploid
copy numbers measured for DEFA3 (0 to 4) and the indel-5 minor allele (0 to
6).
Figure 4.4 The range and frequency of DEFA3 and indel-5 minor allele haplotype copy
numbers.
When haplotype copy numbers of DEFA1A3, DEFA3 and indel-5 minor allele
are combined for the 123 haplotypes, it is seen that not all possible
combinations of haplotypes are observed and that some haplotypes
dominate.
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Table 4.3 This table lists the copy number combinations of the 123 haplotypes inferred from
the 17 CEPH families. **most frequent haplotype in each copy number class, *second most
frequent haplotype in each copy number class
Total Haplotype
Copy Number
DEFA3 Copy
Number
Indel-5 minor allele
Copy Number
Amount (% of
123 haplotypes)
% of same total copy
number haplotypes
1 1 0 1 (0.8) 100
2
0 0 4 (3.2) 14.3
0 1 5 (4) 17.8*
0 2 1 (0.8) 3.5
1 0 18 (14.6) 64.3**
3
0 0 4 (3.2) 11.4
0 1 2 (1.6) 5.7
0 2 10 (8.1) 28.6*
1 0 1 (0.8) 2.8
1 1 18 (14.6) 51.4**
4
0 1 1 (0.8) 5
0 3 8 (6.5) 40**
1 0 4 (3.2) 20
1 1 5 (4) 25*
2 0 2 (1.6) 10
5
0 1 6 (4.9) 17.6*
0 2 1 (0.8) 2.9
0 4 1 (0.8) 2.9
1 1 21 (17) 61.8**
1 2 1 (0.8) 2.9
1 3 2 (1.6) 5.9
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Total Haplotype
Copy Number
DEFA3 Copy
Number
Indel-5 minor allele
Copy Number
Amount (% of
123 haplotypes)
% of same total copy
number haplotypes
2 0 1 (0.8) 2.9
2 1 1 (0.8) 2.9
6
0 2 1 (0.8) 33.3
1 1 1 (0.8) 33.3
2 0 1 (0.8) 33.3
7 1 1 2 (1.6) 100
As was observed for diploid copy numbers of DEFA3 and indel-5 minor allele
(see Section 3.3), an inverse relationship between the haplotype copy
numbers exists for these (Figure 4.5). None of the high-copy haplotypes for
indel-5 minor allele (2 and 3-copy) are also high-copy for DEFA3 (2-copy).
Figure 4.5 A comparison of haplotype copy numbers of DEFA3 and the indel-5 minor
allele. All 2-copy DEFA3 haplotypes overlap with 0 or 1-copy indel-5 minor allele
haplotypes.
This relationship seems to be independent of total haplotype copy number, as
all 2-copy DEFA3 haplotypes have a total copy number of 4, 5 or 6, and the
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highest frequency per repeat unit of the indel-5 minor allele is for haplotypes
with a total of 4 copies, followed by those with 3 copies and then with 5
copies. But all 4-copy haplotypes with 3 copies of the indel-5 minor allele have
either 0 or 1 copy of DEFA3. The same is true for 5-copy haplotypes. Also,
there is an overabundance of 3-copy indel-5 minor allele haplotypes on a
background of 4-copy total as shown in the table below:
Total haplotype
copy number
Frequency of 3-copy indel-5
minor allele haplotypes
3 0.028
4 0.40
5 0.088
6 0
7 0
DEFA3 is human-specific, whereas both alleles of the indel-5 variant are found
in the chimpanzee genome on the UCSC genome browser
(www.genome.ucsc.edu). This fact, coupled with the haplotype copy numbers
observed, supports the hypothesis that the DEFA3 gene arose on a repeat unit
which carried the indel-5 major allele. In other words, this hypothesis may
explain the copy number relationship between the two. Even if this
hypothesis is correct it does not mean that all existing DEFA3-containing
repeats will have the indel-5 major allele because gene conversion events
could have broken down this relationship over time. In fact, a haplotype with
a total of 2 copies with one DEFA3 and two indel-5 minor alleles has been
observed in this study which makes it compulsory for DEFA3 and the indel-5
minor allele to be present on the same repeat unit. This hypothesis can be
checked by sequencing the repeat units using allele-specific primers, for
example. However, it was not explored in this study.
It was also observed that the four main total haplotype copy number classes
(2, 3, 4 and 5) when split according to the number of copies of Indel-5 minor
allele, there are some combinations that dominate in frequency (Figure 4.6).
This is especially obvious in the case of 5-copy haplotypes that largely have
only one copy of the Indel-5 minor allele. The absence of 4-copy haplotypes
that carry two Indel-5 minor alleles is also notable.
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Figure 4.6 Frequencies of each Indel-5 minor allele copy haplotype that make up each of the
four main total copy number haplotypes. These are 117 haplotypes: 28 2-copy, 35 3-copy, 20
4-copy and 34 5-copy.
4.3. Copy Number Haplotypes and SNPs in
Europeans
As mentioned in Section 4.1, of the 64 unrelated individuals from the CEPH
families for whom haplotype copy numbers were obtained, 28 are also
included in the HapMap database. Thus, they are also part of the HapMap
CEPHs typed previously (3.1). Phased SNP genotypes for these 28 individuals
across their genomes are available for analysis from the HapMap website
(www.hapmap.org). From the HapMap genome browser the LD block
encompassing the DEFA1A3 repeats spans about a 120 kb region from
chromosome 8 coordinate position 6,790,000 to 6,960,000 (hg18) (Figure 4.7).
This region also includes the gene DEFA5.
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Figure 4.7 Snapshot of the HapMap genome browser showing the LD block spanning
the DEFA1A3 repeat region, which has almost no genotyped SNPs within it.
There are 131 SNPs genotyped within this LD block on the HapMap database
(data release 24, phase 2). The phased SNP genotypes for the 28 CEPH
individuals were downloaded. Next, haplotype copy numbers of DEFA1A3,
DEFA3 and indel-5 minor allele for these individuals were added on to the SNP
haplotypes. These 56 haplotypes (copy number + SNPs) were sorted in three
different ways: according to total copy number, DEFA3 copy number and
indel-5 minor allele copy number. This analysis was carried out on Microsoft
Excel. The copy numbers haplotypes were grouped in different ways (e.g., low
versus high) and chi-squared test was used to find SNPs that differentiated
between the two classes in question.
Total Haplotype Copy Number and SNPs
The total haplotype copy numbers for these 56 haplotypes ranged from 2 to 6.
Nine were 2-copy, fifteen were 3-copy, thirteen were 4-copy, eighteen were
5-copy and only one was 6-copy. The different combinations of copy number
groups analyzed against each other were:
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Category
ID
Copy
numbers
in group
1
Copy
numbers
in group 2
Number of
SNP(s) with
chi-squared p-
values <0.08
SNP(s) with lowest
p-value (p-value)
A 2 3, 4, 5 and
6
1 rs7814783 (0.05)
B 3 2, 4, 5 and
6
5 rs4300027 and
rs4512398 (0.004)
C 4 2, 3, 5 and
6
2 rs4300027 and
rs4512398 (0.05)
D 5 and 6 2, 3 and 4 29 rs2978591 (0.008)
E 2 and 3 4, 5 and 6 15 rs4300027 and
rs4512398 (1.7x10
-4
)
F 3 and 4 5 and 6 25 rs2978591 (0.017)
G 3 and 4 2, 5 and 6 6 rs2738048 and
rs2738046 (0.042)
H 2 3 0 rs7814783 (0.185)
I 4 5 8 rs2978591 (0.019)
The cut-off value of 0.08 was chosen because it is low-enough, and given the
average p-values obtained, it captures the lowest values in the range. Since
this was a small sample size (56 haplotypes), interest was in SNPs that showed
the lowest value for any given analysis, irrespective of what the value was.
Further information was obtained by comparing the SNP genotypes for the
high-scoring SNPs in the haplotypes in question by eye. However, using a cut-
off value to count how many high-scoring SNPs are found in each analysis tells
us something about the haplotypes: for example, 2 and 3-copy haplotypes
differ the least from each other. Looking at the highest scoring SNPs in each
category, several SNPs are shared between them. This means that some
associations are only weaker replicas of others where more haplotypes have
been included: for example, SNP rs4300027 is the highest scoring in
categories B, C and E. This SNP has the highest chi-squared value in category E
and thus the association shown in the other two categories can be interpreted
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as subsets of this stronger primary association. Similarly, SNP rs2978591 is
common between categories D, F and I, but shows the highest value in D.
The most interesting of all these SNPs is rs4300027 (or rs4512398, which
appears to be in perfect LD with it) because of the low p-value and its ability
to partition haplotypes into low and high copy number categories (2 and 3
against 4 and 5). This SNP is located just outside the centromeric end of the
repeat region at chromosome 8 coordinate 6,867,985. The minor allele (C) is
associated with low-copy haplotypes (2 and 3) and the major allele (T)
associates with high-copy ones (4 and 5). The only 6-copy haplotype in this
analysis has allele C. While none of the 4 and 5-copy haplotypes have allele C,
two 2-copy and two 3-copy haplotypes have allele T. Nevertheless, this meant
that if this association is real and not an artefact of small sample size, then the
genotype of this SNP can be a good proxy for DEFA1A3 copy number classes.
Homozygous Cs would be expected to have diploid copy numbers ranging
from 4 to 6 and homozygous Ts mainly from 8 to 10.
rs4300027 Genotyping and Copy Number Association
To validate the finding of rs4300027 association with copy number haplotypes
in Europeans, an assay was devised to genotype this SNP (Section 2.9) in the
ECACC panel samples that had been assayed with the PRTs and allele ratio
assays for DEFA1A3 copy number (Section 3.1). Combining the genotypes with
the measured copy numbers gave a strong association (regression analysis p-
value = 4.58x10
-28
) replicating the one seen in the HapMap haplotypes (Figure
4.8). The regression was performed in MS Excel by assigning a number to
denote each genotype (1, 2 and 3) and it took into account the number of
samples in each copy number and genotype category.
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Figure 4.8 Strong association of CC genotypes with low copy numbers of 4 to 6 and of
TT genotypes with high copy numbers of 7 to 11. Number of samples in analysis is
159.
DEFA3 Haplotype Copy Number and SNPs
A similar analysis to that for total haplotype copy number was used to test for
association between DEFA3 copy number and SNP haplotypes for the 56
haplotypes from the CEPH families, and 24 more haplotypes from the
HapMap CEPH trios (father-mother-child) were included. In these trios
although haplotype total copy numbers could not be inferred, given the low
DEFA3 copy numbers and its frequent absence DEFA3 haplotype copy
numbers could be determined. Of these 80 haplotypes, 36 had none, 41 had
one copy and 3 had two copies of DEFA3. A comparison was made between
haplotypes without DEFA3 versus those that contained at least one copy. This
comparison showed several SNPs with low chi-squared p-values which
suggests that presence/absence of DEFA3 is a better preserved feature of
haplotypes than total copy number, which changes more often. The highest
scoring SNP in this analysis was rs5028372 with a chi-squared p-value of
1.16x10
-4
. This SNP is located within the partial repeat, and is one of the six
SNPs included in this analysis that are located within the repeat region. While
the other five of these six SNPs are at the periphery and may or may not be in
the copy number variable region, especially the three at the telomeric end
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where the CNV boundary is difficult to determine, rs5028372 is well within
the partial repeat, upstream of the DEFA1A3 locus itself (Figure 4.9).
Figure 4.9 Figure showing the position of SNP rs5028372 with respect to the DEFA1A3
locus.
This causes concern about the validity of the SNP because the sequence in the
partial repeat is almost 99% similar to that in the full repeat (on UCSC genome
browser) and to differentiate between the two in practice seems difficult to
achieve. Thus the question was whether the assay used to genotype this SNP
was actually specific to the partial repeat or not. On the other hand, the fact
that it showed a strong association in the analysis to DEFA3 absence/presence
supports its SNP status and not a multisite variant (MSV) status. On searching
the HapMap database, the details of the assay used were not found.
Indel-5 Minor Allele Haplotype Copy Number and SNPs
As was done for the DEFA3 copy number haplotypes, four additional
haplotypes from the HapMap CEPH trios were obtained for the indel-5 minor
allele copy number. Thus 60 haplotypes were available for this analysis. 14
haplotypes had none, 27 had one, 8 had two and 11 had 3 copies of the indel-
5 minor allele. Given the relationship observed between the haplotype copy
numbers of DEFA3 and indel-5 minor allele (see Section 4.2), it was
unsurprising to find the same SNPs giving a low chi-squared p-value in this
analysis as did for the DEFA3/SNP haplotype analysis, with the reversal of
association. SNP rs5028372 is the highest scoring in this analysis as well, when
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haplotypes with 0 or 1 copy of the indel-5 minor allele are compared against
those with 2 or 3 copies. The minor allele of this SNP associates with 0-copy
DEFA3 haplotypes and 2- and 3-copy indel-5 minor allele haplotypes.
However, for other high-scoring SNPs common between the two, highest
values were obtained in this analysis when 0-copy haplotypes of indel-5 minor
allele were compared against all others.
4.4. Copy Numbers and SNP Genotypes in
Non-European HapMaps
Diploid measured copy numbers of HapMap African, Chinese and Japanese
samples could not be resolved into haplotypes because the Asian samples
were from individuals without any family members included and the Africans
were only in family trios (parents and a child). They could still nevertheless be
investigated for possible associations with SNPs by combining their diploid
copy numbers and SNP genotypes. The genotypes for SNPs in the HapMap
Asian and African samples were also downloaded from the HapMap website.
rs4300027 in Non-Europeans
The major allele of rs4300027 in non-European populations is C instead of T
(ancestral allele and major allele in Europeans is T), with the African
population showing a lower minor allele (T) frequency of 0.23 (Asian
MAF=0.32). The African sample did not show the association with copy
number seen in the European sample and had CC genotypes with diploid copy
numbers ranging from 3 to 17, and the only homozygous T individual had a
copy number of 7. A similar situation was observed for the Asian samples
where CC genotypes spanned diploid copy numbers from 5 to 16, and TT
genotypes from 4 to 10. TC genotypes ranged from 4 to 14-copy individuals.
Since the diploid copy numbers differed significantly between the Chinese and
the Japanese, their copy number relationship with rs4300027 was also
investigated separately. The SNP frequency doesnt change between them;
the Japanese have examples of high copy numbers associated with the C allele
(Figure 4.10), a pattern opposite to that observed in Europeans.
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Figure 4.10 A comparison of the distribution of rs4300027 genotypes with respect to
measured diploid copy numbers in the HapMap populations tested.
Other Copy Number Tags
While the combination of SNP genotypes with diploid copy numbers did not
return any SNPs that could split the samples into copy number classes in the
Africans and Chinese, there are some SNPs that show a weak tagging ability in
the Japanese population. There seem to be two independent SNP blocks on
either side of the repeat region that are in LD with copy number class. The
two prominent SNPs are rs2702879 and rs4284061 at chromosome 8
coordinates 6,793,624 and 6,865,667 on hg18. Their associations with copy
number are shown in Figure 4.11 for the Japanese and other HapMap
population samples. The allele frequencies differ between the four groups: for
rs2702879, allele A is at a frequency of 0.58 in the Japanese, 0.76 in the
Chinese, 0.33 in the Europeans and 0.19 in Africans, and for rs4284061, allele
T is at a frequency of 0.59 in the Japanese, 0.41 in the Chinese, 0.75 in
Europeans and 0.2 in Africans. None of these SNPs have been studied further.
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Figure 4.11 Genotype frequencies for rs2702879 and rs4284061 in the four HapMap
populations
Both these SNPs also seem to separate the Europeans into low, medium and
high copy number classes. SNP rs4284061 does this because it is in weak LD
with rs4300027 (R
2
= 0.59) and shows only three possible haplotypes in
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association with it. The association seen with rs2702879 is probably a subset
of the association this SNP has with Indel-5 minor allele haplotypes. In the
analysis done previously (Section 4.3) it is the best SNP to differentiate
between haplotypes that have no copy of the Indel-5 minor allele and
haplotypes that have at least one copy (chi squared p-value of 0.0069 from 60
haplotypes). Since it has been observed that Indel-5 minor allele copies have a
certain association with total haplotype copy numbers (Figure 4.6) rather than
being randomly associated in the Europeans, a SNP that tags Indel-5 minor
allele presence/absence will likely show a weaker association with total
haplotype copy number. This seems to be independent of rs4300027 (R
2
=
0.14).
It is interesting to note that the SNPs in the DEFA1A3 LD region that show an
apparent CN-haplotype tagging ability in the Japanese have a high allele
frequency difference between the Japanese and Chinese (range from 0.172 to
0.228). The other SNPs in the region that do not show this ability have a lower
spread of allele frequency difference (0.002 to 0.171) (Figure 4.12). Thus the
allele that has become more common in the Japanese in each case is the one
associated with high copy numbers.
Figure 4.12 Graph showing the spread of allele frequency differences between the Chinese
and Japanese samples from SNPs that show a CN-tagging ability in the Japanese and those
that do not
When compared to the allele frequency differences between the Chinese and
Japanese HapMap samples of SNPs from the entire chromosome 8 (total
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182,732 SNPs tested), the CN-tagging SNPs in the DEFA1A3 LD block lie in the
top 2% (Figure 4.13).
Figure 4.13 Graph showing the number of SNPs in each allele frequency difference class,
when allele frequency difference is calculated between the Chinese and Japanese HapMap
samples taking that allele as minor which is minor in the Japanese. The red box highlights the
classes where the CN-tagging SNPs from the DEFA1A3 region lie.
These observations suggest that certain high copy number haplotypes have
become frequent in the Japanese. The difference in the presence/absence of
these haplotypes between the Chinese and Japanese populations seems quite
remarkable given the otherwise genetic homogeneity. Whether this is a
chance happening or a case of selection on the DEFA1A3 locus, it needs to be
investigated further.
4.5. Upstream Replacement
Polymorphism
Discovery and Determination
From a whole genome microarray study for CNVs (Conrad et al., 2010) it was
observed that four individuals had an apparent deletion upstream of the start
of the DEFA1A3 repeat region represented by a decrease in the intensity
ratios (Figure 4.14Figure 4.14).
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Figure 4.14 The average log2 ratios of the four samples exhibiting decrease in ratios
and the average of 16 samples not exhibiting it. X-axis represents the probes
covering the chromosome 8 region from position 6,809,795 to position 6,819,949
(hg18). Y-axis is the average log2 ratios from the microarray experiment.
Since it is in the region in linkage disequilibrium with the repeat region, it was
of interest to be able to type this polymorphism and see if it tagged any copy
number lineages (Figure 4.15). From Perry et als study (Perry, Ben-Dor et al.,
2008) 2 additional HapMap CEPH samples, 3 HapMap Chinese samples and
one HapMap Japanese sample also presented with this deletion. Whereas the
CEPH and Chinese samples had similar decreases in signal intensity ratio
(binary logarithm about -0.9), the Japanese sample had a binary logarithm of -
5 and seemed to be homozygous for the deletion. Primers were designed to
get a short product from samples that carried the deletion. However, all
samples continued to give a full-sized product. Another observation for this
sequence was its similarity to the DEFTP1 sequence in the full repeat. This
sequence had a 16 bp deletion with reference to the DEFTP1 sequence and
primers were designed to amplify across this distinguishing 16 bp that would
bind to both this sequence and the DEFTP1 sequence, thus giving a third PRT
for the DEFA1A3 region (PRT DEFTP1, see Section 2.11).
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Figure 4.15 A shows the location and sequence similarity (87%) of the upstream sequence (labelled US) with
respect to the DEFA1A3 repeats (hg18). Note that the end of the US sequence and beginning of the first Full
Repeat is marked rather arbitrarily, as it is difficult to define this boundary and thus also the end of the FR and
beginning of the next repeat (therefore no chromosome coordinates are assigned to these positions). B shows
the US sequence with some additional sequence where the primer usDEL5-F is placed. Both figures drawn to
scale.
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For reasons not clearly understood, there was a strong bias in the
amplification efficiency of the test and reference loci and the DEFTP1 PRT was
not pursued further. However, it was useful in showing the presence of a
single copy of reference sequence in the samples showing a deletion on the
microarray, by giving test to reference ratios and hence copy numbers
calculated from them double than measured from previous assays. It also
showed absence of the reference sequence in the sample with the apparent
homozygous deletion (HapMap Japanese from Perrys data) (Figure 4.16 A).
Figure 4.16 A shows the electrophoretogram of the PRT products from the HapMap
Japanese sample with a homozygous deletion on the array. Only a test product-sized
peak is obtained. B shows the products from an unchanged sample. It has both test
and reference sized products.
The fact that there was no short product with the primers designed to assay
this deletion, it was hypothesized that it is not in fact a deletion but a
replacement of the sequence with the paralogous sequence in the full repeat
(a gene conversion event). This also explained the absence or reduction of the
reference peaks of DEFTP PRT in samples with a decrease in microarray ratios.
This was tested by identifying sequence differences between the upstream
and full repeat sequences that gave rise to restriction enzyme recognition
sites in either of the two but not both. Then a primer was designed outside
the region of sequence similarity, further upstream, and one within. These
primers are called usDEL5-F and usDEL1-R. The products were digested with
two enzymes. One enzyme (BstUI) would only digest if the sequence came
from the original upstream sequence and the other (EcoRI) would digest if the
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sequence came from the full repeat (Figure 4.17 ). This and another test
where the upstream sequence was specifically amplified and the products
used to seed a second PCR reaction that used the PRT primers, thus
distinguishing the presence of the original or full repeat sequence at the
upstream site by a size difference of 16 bp (data not shown), conclusively
showed that it is a replacement polymorphism.
Figure 4.17 Agarose gel electrophoresis of undigested and digested PCR products of
usDEL5-F+usDEL1-R PCR. Lanes 1, 2 and 3 are from an ECACC sample which gives a
ratio equal to the expected ratio from PRT DEFTP and should only be digested with
BstUI. In lane 1 is the undigested product, in lane 2 is product from EcoRI digestion
and in lane 3 is product from BstUI digestion. Lanes 4, 5 and 6 are from an ECACC
sample which gives a ratio double the expected ratio from PRT DEFTP and should be
partially digested by both enzymes. Lane 4 is undigested, lane 5 is digested with
EcoRI and lane 6 is digested with BstUI. Lanes 7, 8 and 9 are from the HapMap
Japanese showing a homozygous deletion on the microarray and should be only
completely digested by EcoRI. Lane 7 is undigested, lane 8 is digested with EcoRI and
lane 9 is digested with BstUI.
Estimating the junctions of the replacement sequence from the microarray
data, a hypothetical sequence was created that partially matched the
upstream sequence and partially the full repeat sequence. This was then used
to BLAT search in the trace archives (NCBI database) and two exact matches
were found. This was done for both ends of the replacement sequence, thus
allowing definition of the junction point down to a few base pairs. The
sequence around the telomeric end is given in Figure 4.18.
1 2 3 4 5 6 7 8 9 10
3 kb
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Figure 4.18 The reconstructed sequence that had two matches in the trace archives.
The blue sequence exactly matches the upstream sequence, the red sequence
exactly matches the full repeat and the intervening sequence exactly matches both.
The capitalized bases are differentiating ones between the upstream and full repeat
sequences, such that the blue one is the last one that matches the upstream
sequence and the red one is the first one that matches the full repeat sequence.
Hence somewhere between these two is the beginning of the replacement or gene
conversion event.
Haplotypes Containing the Upstream Replacement
Polymorphism
Using the 3-primer assay (usDEL assay, Section 2.11), the 30 HapMap CEPH
trios were typed for the replacement polymorphism. From this typing, 14
haplotypes carrying this polymorphism and 102 not carrying it were
determined, while four haplotypes remained inconclusive because in one trio
all three individuals were heterozygous. The status of this polymorphism was
combined with copy number (where available) and SNP haplotypes. Of the 14
haplotypes carrying this replacement allele, complete copy number data was
available for 5 and indel-5 minor allele copy number was available for a
further 3:
Total copy number DEFA3 copy
number
Indel-5 minor allele copy
number
2 1 0
3 1 0
4 0 0
4 0 0
4 0 0
? ? 0
? ? 0
? ? 1
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The strongest association seems to be with the absence of indel-5 minor
allele. Since this polymorphism has been observed in Europeans and Asians,
but not in Africans so far, it is possible that it is a non-African variant and so
quite recent. One SNP, rs4543566, about 400 bp upstream of this
polymorphism, shows perfect LD with it. The minor allele of the SNP is always
observed in the replacement-carrying haplotypes and the major allele always
in the non-carriers.
4.6. Conclusion and Discussion
Results presented in this chapter have shown how the PRT-based
measurement system for DEFA1A3 when used to type three-generation
families of European origin has allowed inference of haplotype copy numbers
in terms of three components: total copy number, copy number for the DEFA3
gene, and for the Indel-5 alleles. Segregation for this locus has been checked
against the segregation information of surrounding genetic markers. Total
haplotype copy numbers have been found from 1 to 7, a range that was
expected given the measured diploid copy numbers in Europeans (3 to 11).
Haplotype information obtained has also shown characteristics such as
presence/absence of the DEFA3 gene with respect to Indel-5 minor allele copy
numbers. In the 17 families studied, no instance of recombination in this locus
has been observed, at least none that would detectably change copy
numbers. A total of 338 transmissions have been observed, which gives a 95%
confidence on the lower limit on the mutation rate to be 8.86x10
-3
mutations
per meiosis. In contrast, the CNV beta defensin locus on 8p23.1 has been
shown to be highly mutable (~0.7% copy number changing mutations per
meiosis) (Abu Bakar et al., 2009).
Further analysis has been done by combining European copy number
haplotypes with SNP genotypes (from the HapMap database) to search for
potential copy number-tagging SNPs. This has shown several SNPs in good LD
with copy number characteristics of the haplotypes, most notably rs4300027
that differentiates between low and high-copy haplotypes. This association
has been verified by genotyping this SNP in an independent set of European
samples. Non-European HapMap samples do not show associations between
SNP genotypes and diploid copy numbers. However, the Japanese samples
show other distinct copy number haplotypes that are tagged by surrounding
SNPs. Some of them show a weak tagging ability in Europeans and Chinese.
This seems to suggest that this locus has, due to a bottleneck effect and/or
selective forces, acquired distinct features in the European and Japanese
populations by the propagation of only a few haplotypes of the complete total
present in the Chinese and African populations. This was already apparent in
109
the Japanese population from their measured diploid copy numbers, which go
up to 16, while in the Chinese only up to 10. Thus high copy number
haplotypes that may be very rare in the Chinese, have become frequent in the
Japanese. This is why SNPs that differentiate high copy from low copy
haplotypes in the Japanese have different allele frequencies between the
Chinese and Japanese, with the high-copy haplotype associated allele being
much more frequent in the Japanese. Another explanation for this
observation could be that the two populations do not differ significantly, and
the 45 samples from the Chinese population are non-random with respect to
the DEFA1A3 locus, such that high copy numbers have been inadvertently
omitted and therefore also the SNP frequencies are shifted. However, as
stated in Section 3.1, the probability of getting such a high difference based
on chance alone is low (p-value= 1.4x10
-14
).
Thus, rs4300027 or any SNP in complete LD with it can be used as a proxy for
DEFA1A3 copy numbers in Europeans only, and can be genotyped in future
studies for a broad classification of individuals into low, medium and high
DEFA1A3 copy number groups or even p-values for this SNP in already
published GWAS can be investigated as has been done in the next part of this
study (Chapter 5).
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5. INTERROGATING GENOME WIDE
ASSOCIATION STUDIES (GWAS)
Since the first GWAS using SNP microarrays in 2005 (Klein et al., 2005) that
targeted age-related macular degeneration, there have been hundreds more
published to date (1,319 published GWAS till March 2011;
www.genome.gov/gwastudies). These studies are largely SNP interrogating
studies with 100,000 SNPs being the minimum cut-off for consideration in this
catalogue. Large-scale SNP genotyping was made possible because of the
tremendous increases in SNP databases resulting from information from the
human genome sequence (2001, Venter et al., 2001) and the SNP consortium
(Sachidanandam et al., 2001). The second important knowledge-base for
designing and using SNP arrays came from definition of common haplotypes.
This information came from the HapMap consortium (Gibbs et al., 2003).
Since there are only a finite and small number of common haplotypes in a
given population, their knowledge allows using a minimal number of SNPs on
the arrays that are sufficient to impute the genotypes for the excluded ones
(Daly et al., 2001). In the last decade, these databases have grown to include
more and more SNPs, and several human populations (Altshuler et al., 2010),
resulting in increasingly better SNP arrays and thus improving the power and
scope of GWAS. Ultimately, however, in light of economic constraints, the
power of a SNP array to allow discovery is not necessarily directly
proportional to the number of SNPs it genotypes but is affected by choosing
the right set of SNPs dictated by population haplotypes and SNP allele
frequencies (Spencer et al., 2009). Most GWAS have been case-control studies
while others are family-based designs. In case-control association studies,
SNPs that show a significantly different genotype pattern between cases and
controls are considered potentially associated with the phenotype in
question. To get to such associated variants, the raw data is put through
several quality control steps and statistical analyses to both impute excluded
SNPs and remove genotyping artefacts. Also, because a large number of SNPs
are genotyped in each study, and thus a large number of independent tests
are made of the null hypothesis, the p-values need to be corrected for
multiple testing, or in other words a much lower p-value is considered
significant than would be for a single-locus study. Usually, p-values equal to or
lower than 10
-7
-10
-8
are considered significant in GWAS. The reason why real
associations are not always clear-cut is because these studies mostly deal with
complex traits where each contributing locus has low penetrance and thus a
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small effect size. Although care is taken to avoid getting false associations by
matching individuals representative of the two pools as much as possible,
because the number of SNPs typed is so large (>100,000) there still exists
some chance for this error. Many GWAS results are verified by meta-analyses
where data from different studies looking at the same trait may be combined,
and top SNPs are genotyped in an independent set of samples, as was done
for diabetes by the DIAGRAM consortium (Zeggini et al., 2008). This allows
refinement and increased power to detect associated variants.
5.1. SNPs as CNV Surrogates
Whether the associated SNPs found from GWAS are themselves causal or
simply associated with causal variants is determined in the next stage. While
considering CNVs as causal variants the question is how well do SNPs act as
surrogate markers for them if at all. More specifically, when the interest lies in
the dosage-effect of CNV rather than sequence variants in it, SNPs that
differentiate between different copy number classes in a useful manner are
the ones of interest. While SNPs that tag some variant within a CNV
irrespective of the copy number haplotype, they could allow testing the
effects of those variants rather than copy number. For simple CNVs, deletions
and duplications with only two kinds of copy number alleles, there is strong
LD with local SNPs (Hinds et al., 2006). This is because they are also the same
kind of bi-allelic variant that most SNPs are, where the variant has arisen only
once and then spread in the population, with all examples of the derived state
descended from a single ancestor. For multiallelic CNVs, there can be any
number of different alleles resulting through multiple instances of copy
number changes such that the same copy number allele could have arisen
more than once on a different haplotypic background each time. However,
whether there is strong LD or not depends upon the age, genomic structure
and evolutionary history of the CNV in question. As has been shown earlier in
this thesis (see Section 4.3), DEFA1A3 CNV in the European population has
surprisingly good LD with some surrounding SNPs. How many other such cases
exist is unclear as there is a dearth of studies measuring multiallelic CNVs and
examining their haplotypes, but this example is most likely to be an exception
(Locke et al., 2006). The CNVs involving beta-defensin genes (also on human
chromosome 8) and CCL3L1 on the other hand show a breakdown of LD with
surrounding SNPs (unpublished work by R. Palla and S. Janyakhantikul) despite
having lower levels of copy number variation than the alpha-defensin locus in
Europeans. The discussion so far has excluded SNPs within the CNV regions.
Such SNPs would be useless in bi-allelic deletion CNVs, but they may show
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correlation with copy number haplotypes in simple duplications and
multiallelic CNVs. They can also be more difficult to ascertain for SNP-status
and genotype, especially in CNVs with higher copy numbers, and therefore do
not pass the quality control to make it to SNP genotyping arrays.
5.2. rs4300027 as a Surrogate for
DEFA1A3 Copy Number
As described earlier (Section 4.3), a regression analysis of the relationship
between rs4300027 genotype and DEFA1A3 diploid copy number gives a p-
value of 4.58x10
-28
, with the CC genotype associating with lower copy
numbers and TT genotypes with higher copy numbers. The chi-squared p-
value for the distribution of copy numbers in individuals with CC genotypes
when copy numbers are classed into two groups (4 to 7 and 8 to 11) is 3.8x10
-
6
. For TT genotypes, the same analysis gives a p-value of 3.3x10
-6
.
Heterozygotes (TC genotypes) were analysed by grouping copy numbers as
one group of 4, 5, 9, 10 and 11 copy numbers and the other with 6, 7 and 8
copy numbers. The rationale for this partition is that if 2 and 3-copy
haplotypes have allele C and 4 and 5-copy haplotypes have allele T, then
heterozygotes would largely fall in the copy number range of 6 to 8 (2+4=6,
2+5=7, 3+4=7, 3+5=8). Thus the observation of TC genotypes should be
significantly different between the mid-range and tail end diploid copy
numbers. This chi-squared test gives a p-value of 1.5x10
-4
. Of the 159 ECACC
samples typed in this analysis, one CC genotype had a copy number of 7, and
two TT genotypes had a copy number of 6 and thus do not confirm to the low-
versus-high categorization of these genotypes. Similarly, five TC genotype-
individuals had a copy number of 4 or 5, five had a copy number of 9 and one
had a copy number of 10 (Figure 4.8). While there may exist instances of
incorrect copy number assignments to these samples, these deviations
nonetheless should mostly come from the imperfect LD between this SNP and
DEFA1A3 copy number haplotypes. From the initial combination and
comparison of HapMap individuals haplotype copy numbers from segregation
analysis with their SNP genotypes, it was observed that two 2-copy and two 3-
copy haplotypes had allele T. Although none of the 4- and 5-copy haplotypes
had allele C, this observation could be due to small sample size (25
haplotypes). The highest overlap of genotypes in any diploid copy number
class is in 6-copy individuals, and then in 8-copy individuals. This is because a
total of 6 copies can result from either two 3-copy haplotypes, or a
combination of 2 and 4-copy haplotypes. In the first case, the genotype is
likely to be CC, and in the latter case to be TC. Similarly, 8 copies can result
from both 4+4 (TT) and 5+3 (TC). However, these overlaps do not affect so
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much the power of predicting the copy number classes (low, medium, high)
from a given genotype as they do predicting genotype from a given copy
number. For example, if ECACC samples are divided according to their
rs4300027 genotypes, then CC genotypes are 97% low copy number (4, 5 or
6), TC genotypes are 87% medium copy number (6, 7 or 8) and TT genotypes
are 80% high copy numbers (8 or more). As explained earlier, 6-copy and 8-
copy samples will unavoidably overlap two genotype classes.
5.3. Investigating GWAS
Hundreds of different human traits, including many diseases with an
autoimmune component, have been studied through GWAS. The GWAS
database allows one to search for the SNPs with significantly low p-values
from all studies by entering the rs ID of a SNP or a different parameter. A
search with rs4300027 or rs4512398 did not return any study. This was
expected: if it had been a top SNP in a study, although the association with
DEFA1A3 copy number haplotypes would have been unknown, the physical
proximity of it to the DEFA1A3 repeat region (about 800 bp from the
telomeric end) would have led researchers to label these genes as potential
candidates for affecting the phenotype in question. Previously searching the
database with the gene name (DEFA1/DEFA3/HNP1/HNP3) had returned
nothing.
For investigating whether this SNP showed a significantly different distribution
between cases and controls of a disease, much higher p-values, in the range
of 10
-3
, can be considered significant. This is because the issue of multiple-
testing involved in a GWAS does not exist, because we are now investigating
one SNP and not >100,000. This meant that p-values for rs4300027 had to be
looked up in GWAS of interest. However, due to concerns over protecting the
identity of individuals participating in these studies and their genotypes
(Homer et al., 2008), all summary data from GWAS apart from the top hit
SNPs is not made public anymore. Therefore, this investigation involved
drawing up a list of GWAS and contacting relevant authors of the studies with
a request to share the p-value observed for rs4300027 or rs4512398,
whichever was represented on the genotyping array used.
Given the functional role of defensins as antimicrobial and
immunomodulatory peptides, the most likely effect of dosage variation would
be in autoimmune and inflammatory diseases, and those were of primary
interest. The following diseases were investigated:
Coeliac disease results from an autoimmune destruction of the epithelial
lining of the small intestine, which is triggered by proteins in wheat and other
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cereals (Alaedini et al., 2005). The main immune components involved are T-
cells, and their stimulation by antigen-presenting HLA molecules. A strong
genetic predisposition in individuals carrying certain HLA alleles has been
found. GWA studies looking for further genetic factors predisposing to this
disease have been carried out (Dubois et al., 2010). This study has identified
risk loci in genes involved in T-cell development, innate immune detection,
stimulation of B- and T-cells and production of cytokines and their receptors.
Although this disease appears to be a largely lymphocyte-based reaction, the
role of neutrophils in inflammation and influencing the adaptive immune
response may still allow variation in them or their components to affect
disease development (Diosdado et al., 2007). The GWAS by Dubois et al.
studied 4,533 cases (2,586 UK, 647 Finland, 803 The Netherlands and 497
Italy) and 10,750 controls (7,532 UK, 1,829 Finland, 846 The Netherlands and
543 Italy), and should be well-powered to detect such further risk variants.
Inflammatory Bowel Disease (IBD) is a group of chronic inflammatory
conditions of the gastrointestinal tract, the two major ones being Crohns
disease and Ulcerative Colitis (Cho, 2008). Both diseases are characterized by
chronic inflammation of the intestinal epithelia and sometimes one is
misdiagnosed for the other, or they are difficult to tell apart. However, there
are distinct differences in the histopathology and location of the two which
allows their characterization (Cho, 2008). From association studies, some
genetic loci have been found to predispose to one and not the other, and
some are common between the two. For example, a variant of an interleukin
gene, IL23R, is strongly associated with both, and a variant of NOD2, a
receptor for pathogen molecules, is strongly associated with Crohns disease
but not with Ulcerative Colitis. IBDs are thought to result from an abnormal
response to the gut microbes. Neutrophil infiltration is present in inflamed
mucosa and thus varying neutrophil defensins may affect disease
development. Three IBD GWAS have been investigated: one has studied 3,230
cases of Crohns disease and 4,829 controls of European ancestry (Barrett et
al., 2008), second has studied 1,052 cases of Ulcerative Colitis and 2,571
controls of European ancestry (Silverberg et al., 2009) and the third has
studied 1,011 cases of IBD and 4,250 controls of European ancestry
(Kugathasan et al., 2008).
Psoriasis is another chronic inflammatory disease that affects the skin. It is
also considered a T-cell mediated autoimmune disease with infiltration of
various leukocytes and a complex underlying mechanism (Bowcock et al.,
2005). Beta-defensins produced by the skin epithelia are thought to
contribute to disease predisposition and their variable gene copy number has
been found associated with psoriasis risk (Hollox et al., 2005). A role for
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neutrophil defensins was investigated in data from two GWA studies via
rs4300027 association: one studied 318 psoriasis cases and 288 controls of
Northern European descent (Capon et al., 2008) and the other studied 223
psoriasis cases, including 92 cases of psoriatic arthritis, and 519 controls of
European descent (Liu et al., 2008). About 25% of psoriasis patients also
develop psoriatic arthritis which has no correlation with psoriasis severity.
Type-1 Diabetes results from an autoimmune destruction of the insulin-
producing cells of the pancreas. It is the T-cells that destroy the pancreas, and
their recruitment involves cells and signalling molecules of the innate immune
system (Lehuen et al., 2010). The GWAS that was interrogated studied 563
patients, 1,146 controls and 483 family trios, all of European descent
(Hakonarson et al., 2007). This study found an association with a gene coding
for a sugar-binding lectin. Previous studies have found associations with the
insulin locus, HLA locus, T-lymphocyte associated protein 4 and an interleukin
amongst others.
Multliple Sclerosis is another autoimmune disease, in which the immune
system destroys neural cells in the central nervous system. It also has a
complex mechanism, starting with the breakdown of the blood-brain barrier,
resulting in lesions in the brain which are visible on brain scans, and yet it is
not clearly understood how these processes occur (McFarland et al., 2007).
The GWAS that was interrogated studied 931 family trios (affected child and
both parents, 453 from the UK and 478 from the USA) and 2,431 controls
(Hafler et al., 2007). That study identified risk variants in interleukin and HLA
genes.
Atopic Dermatitis is also a chronic and recurrent inflammation of the skin
resulting in lesions that are pruritic and have reduced defence against
microbes (unlike psoriatic lesions, which are highly antimicrobial). The skin of
atopic dermatitis patients, even without lesions, has a higher microbial
burden than normal (De Benedetto et al., 2009). The observed anomalies in
this disease are a breakdown of the skin barrier, decreased innate immune
response and enhanced allergic response. Neutrophils are absent from lesions
despite infection. The GWAS that was interrogated studied 1,468 patients and
1,543 controls, all of European descent (Gordillo et al., 2009). The only variant
shown to affect predisposition to atopic dermatitis is loss-of-function
mutations in the gene coding for filaggrin, which is a component of the skin
barrier.
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Table 5.1 lists the p-values obtained for rs4300027/rs4512398 or an
alternative SNP, rs7825750, in cases where rs4300027 was not genotyped, in
GWAS studying various immunity-related diseases.
Table 5.1 P-values obtained for DEFA1A3 copy number-tagging SNPs in GWAS
studying autoimmune/inflammatory phenotypes and corrected p-values for multiple
testing
Phenotype SNP p-Value** Corrected
Celiac Disease rs4512398 0.013 0.105067161
Crohns Disease rs4512398 0.525 0.997443079
Psoriasis rs4512398 0.2 0.83222784
Psoriasis rs4300027 0.49 0.995915281
rs4512398 0.926 0.999999999
Ulcerative Colitis rs4512398 0.8 0.99999744
rs4300027 0.71 0.999949975
IBD and T1D* rs4512398 >0.05
rs4300027 >0.05
Multiple Sclerosis rs7825750 0.5904 0.999207718
Atopic Dermatitis rs7825750 Not significant
*IBD= Inflammatory Bowel Disease, T1D= Type-1 Diabetes
** We are grateful to the following people for sharing their GWAS data: David
van Heel, Michel Georges, Richard Trembath, Anne M. Bowcock, Richard H.
Duerr, Hakon Hakonarson, Young Ae-Lee and Stephen Sawcer.
As the table shows, none of the studies have significant or even suggestive p-
values for rs4300027. The lowest uncorrected p-value is 0.013 in the celiac
disease GWAS, which is ten times higher than the 10
-3
range considered
significant in such a large study. In some genotyping platforms, neither
rs4300027 nor rs4512398 was included. In those cases the next best available
SNP was rs7825750, which gave a correlation coefficient of 0.3 with haplotype
copy numbers divided into low (2 and 3) and high (4 and 5) (rs4300027 gave a
value of 0.67). Since p-values (either for rs4300027 or rs7825750) from eight
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independent GWAS were interrogated, this increases the probability of
finding an association purely by chance than if only one GWAS was
investigated. Thus, each p-value is corrected for multiple testing, i.e. of testing
several studies, by applying the formula 1-(1-p)
n
, where p denotes the p-value
reported in the GWAS, and n is the number of GWAS investigated.
5.4. Conclusions and Discussion
SNP rs4300027 is a good proxy for DEFA1A3 copy number in Europeans, as
evidenced by percent accuracy of predicting diploid copy number class (low,
medium and high) from genotypes. This means that for large-scale studies in
the European population DEFA1A3 copy number can be effectively measured
by genotyping this SNP and avoiding the more cumbersome process of
genotyping the CNV itself, as long as broad copy number class is a good
enough measure. This useful property has been exploited to investigate
GWAS which have studied phenotypes where neutrophil alpha defensins
might play a role. These GWAS are well-powered with sample sizes ranging in
the thousands. In the seven disease phenotypes investigated here, none has
returned a significant p-value for rs4300027 (or SNPs in LD with it). As
discussed earlier (Section 5.1), other multiallelic CNVs that have been studied
by others do not show linkage with surrounding markers in a way that would
allow using them as surrogates for copy number.
Here an assumption has been made, implicit so far, that gene copy numbers
of DEFA1A3will directly affect protein levels such that higher the copy
number, greater the protein expression level. In reality, it is unknown how
expression levels are affected by this CNV. The next chapter details a
methodology for quantifying gene expression of DEFA1A3, and this is an
instance where the exact copy number of each sample tested is of interest,
rather than which of the three broad copy number classes it belongs to.
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6. EXPRESSION OF DEFA1A3 GENES
6.1. Synthesis of DEFA1/2/3 peptides
Transcription and translation of DEFA1 and DEFA3 genes occurs in the
neutrophil precursors, the promyelocytes in the bone marrow, and is not
normally observed in other body tissues (Daher et al., 1988). The exceptions
found by Daher et al are tissues where neutrophils or their precursors are
present (for example, peripheral blood in leukemia patients) and eosinophils
have also been shown to produce alpha defensins (Driss et al., 2009), thus
restricting the production of these peptides to the myeloid lineage of blood
cells. However, neutrophils are the largest source both because defensins
make up almost 5% of total neutrophil protein content (1 to 5 µg per 10
6
neutrophils) (Ganz, 1987, Harwig et al., 1992) and because neutrophils are the
most abundant white blood cells (50% to 70% of total white blood cells),
whereas the other granulocytes, basophils and eosinophils are the least
frequent (0.5% to 3% of total white blood cells) in normal individuals. Further
evidence of myeloid-specific expression of these genes comes from studies of
their transcriptional control. It has been shown that a CCAAT/enhancer-
binding protein (C/EBPɲ) positively regulates the transcription of DEFA1 and
DEFA3, and does so equally well for both (Tsutsumi-Ishii et al., 2000).
Experimental removal of C/EBP binding site in the defensin genes promoter
region does not abolish transcription but reduces it to less than half. However,
in Specific Granule Deficiency (SGD) caused by loss-of-function mutations in
C/EBPɸ gene, besides absence of secondary and tertiary granule proteins in
neutrophils, alpha defensins are also reduced (Gombart et al., 2001,
Lekstrom-Himes et al., 1999). The link between C/EBPɲ and C/EBPɸ is most
probably that C/EBPɲ controls the expression of C/EBPɸ which has been
shown to be specific to the myeloid/lymphoid progenitors, and C/EBPɲ has
been shown to act earlier in the development of these lineages (Lekstrom-
Himes et al., 1998).
The mRNAs for these defensins (as for others) code for a pre-prodefensin
peptide that is 95 amino acids long and includes a signal peptide at the amino
terminal, followed by a propiece and then the mature peptide (Valore et al.,
1992). This pre-prodefensin is processed to a 75 amino acid long prodefensin
by the cleavage of the signal peptide sequence. This is then further processed
to a 56 amino acid prodefensin, which is cleaved to give the 30 amino acid
DEFA1 and DEFA3, and the 29 amino acid DEFA2 mature peptides. Valore et al
found this processing to take 4 to 24 hours in normal and leukemic cultured
cells. Harwig et al also report other intermediate prodefensin peptides of 39,
34 and 32 amino acids in the neutrophils but in minute amounts (0.25% of
total defensin content) (Harwig et al., 1992).
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Figure 6.1 Amino acid sequence of DEFA1/2/3 (HNP-1/2/3) (Valore et al., 1992)
The defensins are packaged in the azurophil (primary) granules of the
neutrophils. The propiece is necessary for the targeting of the peptide to
these granules and processing to the active form takes place post-packaging
(Gullberg et al., 1999). Also, the development of the three main granules of
neutrophils (azurophil, specific and gelatinase) occurs in a temporally
stratified sequence and the timing of the production of granule proteins
influences which granules they are sorted to (LeCabec et al., 1996).
Before any concrete knowledge of the highly polymorphic CNV of DEFA1A3,
the lower copy numbers of DEFA3 as compared to DEFA1, and the absence of
the DEFA3 gene in some proportion of the human population was available, it
was already observed that the DEFA1 peptide accounted for a larger
proportion of total neutrophil defensin content than the DEFA3 peptide
(Chertov et al., 1996). With a much better characterization of this CNV, how it
affects expression levels is an interesting and obvious next question. As shown
by Tsutsumi-Ishii et al, the promoter and enhancer (C/EBP binding site) are
within 200 bp upstream of the first exon of the gene. However, there could be
several other factors influencing gene expression in the complex CNV
arrangement and only a direct measurement of gene copy numbers and of
gene expression will address this question. The measurement of genes has
already been discussed in the previous chapters. For gene expression
measurements, neutrophils are an easily obtained cell type from the blood as
opposed to obtaining promyelocytes from the bone marrow. This exclusion of
promyelocytes means that gene expression has to be studied at the protein
level rather than mRNA level. Aldred et al used neutrophils for defensin mRNA
quantification and found no correlation with total gene copy numbers (Aldred
et al., 2005). They did find that DEFA1:DEFA3 gene ratio correlated with
DEFA1:DEFA3 mRNA ratio, and acknowledged that protein measurements
from neutrophils would give a more accurate quantification of expression.
6.2. Neutrophil variability
Neutrophils are the most abundant of the white blood cells (60% to 70%) and
also very variable in number from person to person. Some variation in
neutrophil counts depends upon age, sex, ethnicity and even time of day, but
even within people matched for these factors, there is great variability.
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Further variation comes from infection or other pathophysiological
differences which may not be apparent or measureable, and hence cannot be
accounted for. This high variability is possible because of their high turnover
rate: neutrophils survive for at most 5 days in the blood (Pillay et al., 2010). In
healthy, European adults (median age = 25 years) neutrophil counts range
from 1500 to 6500 million per litre of blood (Greer, 2009). This means that
rather than taking all neutrophils from the same volume of blood as a starting
source of defensins, neutrophils need to be counted for each blood sample
(even when repeating for the same individual). Section 13 of Chapter 2
describes the methods used to obtain granulocytes (neutrophils, eosinophils
and basophils) and count them. To demonstrate the separation of
granulocytes from other blood cells, Figure 6.2 and Figure 6.3 show
micrographs of stained slides of whole blood and separated granulocytes.
About 97% of the separated cells were granulocytes which is the expected
frequency from the protocol used.
Figure 6.2Micrograph of Leishman-stained whole blood smear (400x). Arrow points to
a neutrophil.
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Figure 6.3Micrograph of Leishman-stained separated granulocyte smear (400x). Cells
have lost some volume during the processing and appear smaller than in whole
blood.
6.3. Determining Alpha Defensin
Peptides in Neutrophil Extracts
Separated neutrophils were treated with acetic acid (as described in Section
2.13) to extract proteins, including granule proteins. To confirm the presence
of defensins in the neutrophil extracts, the extracts were subjected to 18%
Tris-tricine SDS PAGE. The molecular weight of neutrophil defensins (DEFA1,
2, 3 and 4) is 3.5 to 3.9 kDa. Since most neutrophil proteins are bigger than
this size and since defensins are present in large quantities, the band in the
gel corresponding to 3.5 to 4 kDa size would contain only or mostly the
defensin peptides as has been demonstrated previously (Ganz et al., 1985).
This band was cut out and sent for sequencing to another laboratory (Figure
6.4). Note that since a small gel (8 x 10 cm) was used, the resolution is poorer
than obtained by Ganz et al on a longer gel. Better resolution was obtained in
later experiments using large gels (18 x 20 cm) (Figure 6.5). Note that the well
separated defensin band in the large gel is not of an intensity expected of a
peptide that makes up 5% of neutrophil proteins, and that is due to poor
fixation of small sized peptides in gels after electrophoresis. The band
containing the defensin peptides in the smaller gel is more intense probably
because it contains other peptides as well due to poorer resolution.
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Figure 6.4 Photograph of a Coomassie Blue-stained SDS PAGE gel (18% Tris-tricine)
with two samples of granulocyte extracts from 10
6
cells each and a protein ladder in
the right most side. The bands from the cell extracts that correspond to the size of
alpha defensins and that were sequenced are highlighted in the red box
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Figure 6.5 Photograph of a Coomassie blue-stained Tris-tricine SDS PAGE (18%) with
magnified image of the gel area with the defensin bands (indicated with black arrow)
below. Lanes 3 and 6 are protein ladders, lanes 1, 4 and 5 are extracts from 5x10
5
neutrophils and lane 2 is extracts from 10
6
neutrophils.
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The sequences of the neutrophil peptides are:
(DEFA1) ACYCRIPACIAGERRYGTCIYQGRLWAFCC
(DEFA3) DCYCRIPACIAGERRYGTCIYQGRLWAFCC
(DEFA2) CYCRIPACIAGERRYGTCIYQGRLWAFCC
(DEFA4) VCSCRLVFCRRTELRVGNCLIGGVSFTYCCTRVD
However, the sequencing method used was not able to determine Cysteines
(Edman degradation method) and only the first six residues were sequenced.
Additionally, the sample sent for sequencing came from a person without the
DEFA3 gene (determined by the DefHae3 assay, Section 2.2) which meant that
the sequence expected was a mixture of the following three:
(DEFA1) A-Y-RI
(DEFA2) -Y-RIP
(DEFA4) V-S-RL
The sequencing results obtained are shown in Figure 6.6. The first amino acids
are as expected Ala and Val, the second includes Tyr (from DEFA2), the third is
Tyr (from DEFA1) and Ser (from DEFA4), the fourth includes Arg (from DEFA2),
the fifth should have been predominantly Arg (from DEFA1 and DEFA4) but is
only weakly detected for some reason and Ile (from DEFA2), the sixth is as
expected predominantly Ile (from DEFA1), but no Pro (from DEFA2) or Leu
(from DEFA4) are detected. It was indicated that Pro residues are often not
recognized (personal communication with the sequencing lab). There are
clearly some other sequences mixed with the defensins which give a His at
position 2, Asn at 3, Lys at 4 and Ala at 5. These could come from other similar
sized proteins or proteolytic fragments from larger proteins in the
neutrophils. Since these could be a complex mixture and defensins were
identifiable despite their presence, no attempt was made to identify the
contaminants.
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Figure 6.6 The result of peptide sequencing. Single letters represent amino acids, with
those in the left most column being the predominant ones at the corresponding
position and those in the right most column being the least concentrated ones.
6.4. Acid Urea PAGE
Acid urea Polyacrylamide gel electrophoresis (AU PAGE) was carried out for
neutrophil extracts as described in Section 2.13. The purpose of this
electrophoresis system is to allow separation of very similar or same-sized
proteins, such as DEFA1, 2 and 3 on the basis of charge differences due to
differences in amino acid composition. At the low pH of the gel (about 3) even
amino acids with the lowest pKa are protonated, resulting in a positive charge
on all proteins and therefore migration is from anode to cathode (as opposed
to cathode to anode in an SDS PAGE system). Separation occurs on the basis
of both mass and strength of the positive charge on the proteins. In this
experiment no standard defensin peptides for reference were included in the
gel, nor were the separated peptides confirmed by a Western blot or any
other means. Since separation on an AU PAGE is based on both size and
charge of the proteins, there are no standard markers available. Thus the only
means of hypothesizing which of the bands correspond to the defensins was
by comparing the obtained profile with that obtained by previous studies,
Linzmeier and Ganz in this case (Linzmeier et al., 2005) (Figure 6.7). The band
containing the DEFA3 peptide could be either of the two bands marked with
red arrows, as the DEFA3- individual in lane 2 has several bands missing in the
profile and not just the DEFA3 band as it ideally should have.
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Figure 6.7 The top part of the figure has been taken from LInzmeier et al (Linzmeier et al.,
2005), where part A shows a Coomassie blue-stained AU PAGE where the first three lanes
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contain standard defensin peptides, lanes 4 and 5 contain neutrophil extracts from
individual(s) lacking DEFA3, and lane 6 contains neutrophil extract from an individual
possessing DEFA3. Part B shows the western blot. The gel at the bottom is from this study,
where the left most lane contains neutrophil extract from a DEFA3+ individual and the right
most lane contains neutrophil extract from a DEFA3- individual. The band corresponding to
DEFA3 is more likely to be the upper band marked with a red arrow, as it corresponds better
with the position of bands with respect to Linzmeier et als AU PAGE.
6.5. Quantifying Alpha Defensin Peptides
(DEFA1/2/3)
For quantification of the alpha defensins peptides, ELISA was used (see
Section 2.13). Three samples were typed in duplicate using purified defensins
as standards. The standards ranged in concentration from 0.07 to 10 ʅg/ml.
Their absorbance values (at 450 nm) recorded at the end of the ELISA are
plotted against their concentrations in Figure 6.8.
Figure 6.8 Graph showing absorbance values obtained from the ELISA of defensin
standard proteins
Given the defensin amounts estimated previously, concentrations of 10
5
granulocytes per ml were used for analysis. Three samples were tested in
duplicate, i.e. two extracts from the same sample were tested in the same
experiment. The absorbance recorded was used to calculate defensin
amounts using the standard curve (Figure 6.8) by non-linear regression
equation in GraphPad Prism software. These calculated amounts are plotted
against the measured DEFA1A3 gene copy numbers for the same samples
(Figure 6.9).
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Figure 6.9 Calculated defensin amounts from ELISA end-point absorbance values
plotted against measured gene copy numbers.
The standard deviation between the duplicates of two samples (copy numbers
7 and 8) are low (0.009 and 0.028, respectively), but for the third sample is
quite high (0.485) as is evident from the data points on the graph. It is not
possible to infer any relationship between gene copy numbers and protein
amounts from this data as it has only three samples out of which one is highly
inconsistent.
6.6. Investigating a Role for Alpha
Defensins in Cystic Fibrosis
Cystic Fibrosis (CF) is an autosomal recessive disease that is
characterized by pancreatic malfunction due to its fibrosis, and fatally
abnormal lung function due to clogging of airways with mucus, resultant
chronic infections and fibrosis of lung tissue (Davis, 2006). The current median
age of survival is between 30 and 40 years (Davis, 2006). The genetic cause is
a loss-of-function or decrease-of-function mutation in the Cystic Fibrosis
Transmembrane conductance Regulator (CFTR) gene (Riordan et al., 1989).
This gene codes for a membrane channel that is responsible for active
transport of chloride ions across the cell membrane. Mutations in CFTR lead
to decreased or absent activity of this channel and when a person inherits two
mutated copies of the gene, it can result in CF. This membrane channel is
expressed in several organs of the body, mainly in cells of the epithelial tissue
that line the airways, intestines, and exocrine ducts. These are all sites of
production of fluids: mucus, digestive fluids or other exocrine secretions like
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sweat and saliva. A sub-optimal function of pumping out chloride ions results
in a change of osmotic pressure across the apical surfaces of these cells that
causes more water to enter the cells and results in thickening of the
extracellular fluids.
CF Genetics
The CFTR gene is about 203 kb and the protein is 1,480 amino acids
long. As of December 2011 the number of CFTR gene mutations catalogued in
the database is 1,897 (www.genet.sickkids.on.ca/StatisticsPage.html). These
also include mutations in regulatory regions of the gene. Not all of these
mutations result in CF, though they may cause or predispose to other
pathologies, which also co-occur with CF. These include pancreatitis and
congenital bilateral absence of vas deferens amongst other symptoms.
Whether the two mutations inherited by a person will cause CF depends upon
the nature of the mutations and how much CFTR function is affected
(Griesenbach et al., 1999). CF results when CFTR function is less than 10% of
normal. Pancreatic insufficiency occurs only at a lower residual CFTR function
of about 5% or less ?KĨĂůůƚŚĞƐĞŵƵƚĂƚŝŽŶƐ ?ȴ& ? ? ? ?ĚĞůĞƚŝŽŶŽĨƉŚĞŶǇůĂůĂŶŝŶĞ
at position 508) is the most common: it has been found to have a relative
frequency of 0.67 among disease-causing mutations in a combined cohort of
European, north African and west Asian populations (Lao et al., 2003).
However, the frequency varies between these populations in a clinal fashion:
it is highest in northern Europeans, followed by southern Europeans, west
Asians (Turkey, Lebanon and Israel) and least in Tunisians. Since Europeans
have the highest carrier frequency of CF mutations (1 in 25 people in the UK is
ĂĐĂƌƌŝĞƌ ?ĂŶĚȴ& ? ? ?ƉƌĞĚŽŵŝŶĂƚĞƐĂŵŽŶŐƐƚƚŚĞŵĂůů ?ĨƵƌƚŚĞƌĚŝƐĐƵƐƐŝŽŶǁŝůů
pertain to this mutation and patients homozygous for it. It is rare to observe
homozygotes for other CFTR mutations, and studies of those cases are limited
(Stanke et al., 2008) ?ȴ& ? ? ?ƌĞƐƵůƚƐŝŶĂ&dZƉƌŽĚƵĐƚƚŚĂƚŝƐĂďŶŽƌŵĂůůǇ
processed (Sharma et al., 2004). It has been shown that the protein is
retained in the endoplasmic reticulum and >99% is degraded (as opposed to
75% of normal protein). Furthermore, if this mutant protein reaches the apical
membrane of the cell it is abnormally internalized and marked for
degradation.
Why Study CF?
ůƚŚŽƵŐŚȴ& ? ? ?ŚŽŵŽǌǇŐŽƚĞƐŚĂǀĞ& ?ƚŚĞůƵŶŐĚŝƐĞĂƐƉŚĞŶŽƚǇƉĞŝƐ
highly variable showing low correlation to CFTR genotype as opposed to the
high correlation between pancreatic disease and CFTR genotype (Hamosh et
al., 1993), but it does show a genetic contribution to this variability rather
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than only an environmental contribution (Vanscoy et al., 2007). Since CF is the
most common severe genetic disease in Europe, and the major cause of
mortality is lung disease, it is of great interest to find other genetic factors
that modify disease severity. Given the lung pathology observed in CF patients
and discussed under the following heading, alpha defensins become an
interesting potential modifier locus.
CF Lung Disease
Lung disease may be the major killer in CF but despite tremendous
research to understand its development it remains the least understood of all
CF manifestations (Boucher, 2004). CF patients are born with normal lungs.
The basic defect of CF results in abnormal airway surface liquid (ASL) volume
and tonicity that leads to impaired clearance of the airways by adversely
affecting the normal ciliary movement and the lungs defence mechanisms.
This allows microbes that are not pathogenic in normal lungs to infect CF
airways and establish chronic infections, which the immune system cannot
clear. How the innate immune system of the lungs is affected by the basic
defect of CF remains poorly understood. It was initially thought that the ASL in
CF patients has a higher salt content than normal which inhibits antimicrobial
peptides like the beta defensins produced by the lung epithelia (Goldman et
al., 1997). However this hypothesis has been challenged by studies showing
that there is no difference in the tonicity of ASL between CF patients and
normal controls (Knowles et al., 1997). An alternative hypothesis implicates a
decreased volume of ASL in impaired airway clearance and immune function
(Matsui et al., 1998). In either case, it is not disputed that the innate immune
function of the airways is impaired, leading to infections by opportunistic
pathogens. An almost characteristic chronic infection in CF lungs (especially in
older patients) is that of Pseudomonas aeruginosa (Brugha et al., 2011). This
bacterium is easily cleared from normal airways without causing any
inflammation. Besides the higher-than-normal susceptibility to infections,
inflammation is also considered to play a role in the deterioration of the CF
airways. Not only this, but inflammation and increased pro-inflammatory
cytokines and cells are seen to occur prior to any infections (Khan et al., 1995,
Tirouvanziam et al., 2002). This increased inflammation is thought to occur
because of abnormal neutrophil recruitment and to result in epithelial
damage and facilitation of microbial adherence (Plotkowski et al., 1989). In
contrast, other studies have found no change in pro-inflammatory cytokine
concentrations or other evidence for inflammation prior to infection in CF
lungs (Aldallal et al., 2002, Muhlebach et al., 2004).
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Components of Airway Innate Immunity
The airways are constantly exposed to microbes in inhaled air.
Mechanical clearance consists of the mucus lining the epithelia that functions
to trap particulate matter which is cleared out via the beating of the cilia of
the epithelial cells (mucociliary clearance) (Houtmeyers et al., 1999). Chemical
immunity includes pathogen recognition molecules (Toll-like receptors, for
example) on the surface of epithelial cells and secretion of antimicrobial
substances, and inflammatory and chemotactic mediators (Bals et al., 2004).
These not only directly eliminate bacteria but also recruit neutrophils in case
of establishment of infection (Craig et al., 2009). While insufficient neutrophil
infiltration can result in persistent infection, a high neutrophil accumulation
can cause injury to lung tissue by increased and/or prolonged inflammation.
Neutrophils are present in large numbers in the lung vasculature as compared
to the bigger blood vessels because of their slower passage (Doerschuk et al.,
1993). This facilitates their quick recruitment into the airways.
CF Lung Disease and Modifier Loci
Several studies have been undertaken to find genetic loci that act as
modifiers of lung disease severity. Earlier studies focused on immunity-related
genes and more recently genome-wide association studies have been
performed. While some loci have given conflicting results, some have shown
clear association or lack of it. However, the variability remains largely
unexplained. Lung function is the standard diagnostic and prognostic
measure of lung disease in CF (Ranganathan et al., 2008, van der Ent et al.,
1999), and is used as the variable phenotype in most association studies. Lung
function is measured by spirometry in terms of Forced Expired Volume in one
second (FEV1) and Forced Vital Capacity (FVC) in case of adults and children
aged 6 years or older. In younger children, more complicated techniques are
adopted. Children under 6 years of age are usually not included in association
studies.
Anti-proteases, like ɲ1-antitrypsin (ɲ1-AT), are present normally in the
ASL and balance the presence of proteases, like neutrophil elastase,
metalloproteases and others (Garcia-Verdugo et al., 2010). In CF, increased
proteases have been detected in the lungs (Birrer et al., 1994). Studies have
looked at ɲ1-AT deficiency and CF lung disease and found conflicting results:
increased susceptibility to P.aeruginosa infection but no adverse effect on
lung function (Doring et al., 1994), beneficial effect on lung function
(Mahadeva et al., 1998), and no effect on lung function (Frangolias et al.,
2003). Although these three studies included A?& ? ? ?ŚŽŵŽǌǇŐŽƚĞƐ ?
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heterozygotes and non-A?& ? ? ?&ƉĂƚŝĞŶƚƐ ?ƚŚĞĞĨĨĞĐƚŽĨɲ1-AT haplotypes was
also studied in A?& ? ? ?ŚŽŵŽǌǇŐŽƚĞƐĂůŽŶĞ ?
Tissue Growth Factor-ɴ (TGF-ɴ) is a cytokine that can promote fibrosis
of tissue and affect inflammatory response (Sporn et al., 1986). A high-
expressing TGF-ɴ haplotype has been found associated with a faster decline in
lung function in CF (Arkwright et al., 2000). Another study looking at 16
polymorphisms previously reported to be associated with CF lung function
found TGF-ɴ haplotype as the only significant association in >800 A?& ? ? ?
homozygotes (Drumm et al., 2005). Other loci tested in this study included
Tumor Necrosis Factor-ɲ (TNF-ɲ), Mannose-binding Lectin (MBL), Interleukin-
10 (IL-10), Nitric Oxide Synthase 3 (NOS3), ɲ1-antiprotease (ɲ1-AP) and
Angiotensin Converting Enzyme (ACE) amongst others. These TGF-ɴ
haplotypes associated with CF have also been found to affect disease
progression in idiopathic pulmonary fibrosis (Xaubet et al., 2003).
A recent GWAS using a SNP platform of 2.3 million SNPs has found two
loci in significant association with lung disease severity in CF patients (1,978
A?& ? ? ?ŚŽŵŽǌǇŐŽƚĞƐĂŶĚƌĞƉůŝĐĂƚĞĚŝŶ ? ? ?A?& ? ? ?ŚŽŵŽǌǇŐ ƚĞƐ ?(Wright et al.,
2011). The nearest genes to these loci (SNPs) are ones coding for epithelial-
specific transcription factors, a protein involved in inhibiting apoptosis, a
neuromodulatory protein and a melanocortin receptor. They found p-values
for TGF-ɴ in the range of 10-3 to 10-4 dependent upon covariates, but higher
values on its own at the genome-wide level.
Beta-defensins are produced by the lung epithelia. A study of the beta-
defensin CNV has shown no significant modifying effect on CF lung disease
severity (Hollox et al., 2005). This study looked at 355 patients, of which about
45% were A?& ? ? ?ŚŽŵŽǌǇŐŽƚĞƐ ? ? ?A?ǁĞre A?& ? ? ?ŚĞƚĞƌŽǌǇŐŽƚĞƐĂŶĚƚŚĞƌĞƐƚ
had non-A?& ? ? ?ŵƵƚĂƚŝŽŶƐŽŶďŽƚŚĐŽƉŝĞƐŽĨCFTR. This is the only study that
has directly measured a copy number variable locus in CF patients.
Alpha Defensins as a Modifier Locus
Neutrophil alpha defensins are not only antimicrobial but have been
shown to be anti-inflammatory (Miles et al., 2009). Given the infiltration of
neutrophils in the CF lung, and the abundance of alpha defensins in
neutrophils, both these properties could make them an important player in
the lung pathogenesis of CF. Given the difficulty in studying CF lung disease
development that has often led to contradictory results for the same
questions, there is no obvious direction to a prior hypothesis that a low or a
high copy number of DEFA1A3 would enhance or decrease lung function, if at
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all. In this study, the effect of DEFA1A3 CNV on CF lung disease severity has
been explored through two routes:
A. DEFA1A3 Copy Number Measurement in CF
Patients
This is a direct study of the alpha defensin CNV in a cohort of 270 UK CF
patients in collaboration with Dr. Jane Davies (Imperial College London). Lung
function data has been collected for these patients allowing their grouping
into mild and severe disease, and this information is available to Dr. Davies
and her group only. Anonymized DNA samples were received for DEFA1A3
analysis. Copy number measurements were done using PRT MLT1A0, PRT
DEFA4-406, DefHae3 and Indel-5 assays. SNP rs4300027 was also genotyped.
The samples used as calibrators for the PRTs were HapMap CEPH samples that
were also part of the 3-generation CEPH families typed and there was high
confidence in their measured DEFA1A3 copy numbers. The graph below
shows the level of concordance between the measured copy numbers from
the two PRTs (231 samples had results from both PRTs).
Figure 6.10 Comparison of copy numbers measured from the two PRTs for 231 CF
samples.
It was noticed that copy numbers from PRT DEFA4-406 tended to be higher
than those from PRT MLT1A0 (Figure 6.10). In such cases, copy numbers
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measured from PRT DEFA4-406 were more often closer to the MLCN (about
81% of times), which takes into account ratios from the Indel-5 and DefHae3
assays, than PRT MLT1A0 copy numbers, indicating a likelihood of bias in
errors, with more from PRT MLT1A0. A correction to all PRT MLT1A0
measurements was tested, but it did not improve the overall accuracy of copy
number measurements, as determined by the minimum ratios from the MLCN
program (see Section 2.4) and copy number correlation with rs4300027
genotypes. Thus, the correction was not applied.
The copy number measured for one sample from PRT DEFA4-406 (9 copies)
was about twice as high as that from PRT MLT1A0 (4 copies) (Figure 6.10).
This was tested and found to be a carrier for the DEFA4 gene deletion (see
Section 2.10).
The overall copy number range and distribution for the 270 CF samples did
not vary significantly (T-test p-value= 0.99) from the general population
(ECACC and CEPH samples) as was expected (Figure 6.11).
Figure 6.11 Comparison of the range and frequency of measured DEFA1A3 copy
numbers from CF patients and normal controls
SNP rs4300027 genotypes show the same correlation with copy number as
had been observed in the general population (ECACCs):
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Figure 6.12 Comparison of rs4300027 genotype frequency distribution in DEFA1A3
copy number classes of ECACC samples (top graph) and CF samples (bottom graph)
Results of Analysis
Copy number data (total and for DEFA3) and rs4300027 genotypes for the 270
CF samples was sent to Dr. Davies for analysis with patient phenotype. They
found no significant association of FEV1 with total copy number (ANOVA p-
value 0.17), with DEFA3 copy number (ANOVA p-value 0.6), or with genotype
(ANOVA p-value 0.7). They also found no significant association of genotype
with pancreatic sufficiency (chi-squared p-value 0.96), with Staphylococcus
aureus infection (chi-squared p-value 0.1), with MRSA infection (chi-squared
p-value 0.36), with Pseudomonas aeruginosa infection (chi-squared p-value
0.97), with Stenotrophomonas maltophilia infection (chi-squared p-value
0.76), with Aspergillus fumigatus infection (chi-squared p-value 0.27) or with
allergic bronchopulmonary aspergillosis (chi-squared p-value 0.9).
B. SNPs as Copy Number Surrogates
The other approach to look for association between DEFA1A3 copy number
and CF lung disease severity was to exploit existing SNP genotypes from a
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large-scale GWAS, by examining p-values obtained for copy number-tagging
SNPs (4.3) (Wright et al., 2011). Table 6.1 shows the p-values obtained.
Table 6.1 List of SNPs and the haplotype features they potentially tag, and their p-values in
the Cystic Fibrosis GWAS
SNP Haplotypes Tagged p-value for
A?& ? ? ?
homozygotes*
p-value for all
samples**
rs4300027 2 and 3-copy versus 4
and 5-copy
0.05 0.1
rs4512398 as above 0.06 0.12
rs2702852 DEFA3 presence/absence 0.02 0.02
rs2738058 as above 1 1
rs6984215 5-copy versus others 0.13 .09
*1,978 individuals
**includes 1,978 A?F508 homozygotes and 516 other CF genotypes
rs4300027 is the only SNP for which the LD with copy number haplotypes has
been tested and replicated in ECACC samples (see Section 4.3). rs4512398 is in
perfect or almost perfect LD with it, and so both SNPs result in similar p-
values in this study. However, the p-values are not low enough (in the 10
-3
range) to suggest a significant effect of total DEFA1A3 copy number on lung
disease variability. DEFA3 presence/absence tagging SNPs (rs2702852 and
rs2738058) have been chosen from their apparent association observed in
only 80 CEPH haplotypes (p-values 3.9x10
-3
and 7.8x10
-3
) and rs6984215 from
56 CEPH haplotypes (p-value 0.013). There is no independent verification of
their association and any could be a false positive. The lowest p-value
observed is 0.02 for rs2702852 which has an apparent DEFA3 gene presence
tagging ability. The other SNP chosen for the same haplotype feature,
rs2738058 is in weak LD with rs2702852 (R
2
=0.5 from 120 haplotypes). Thus
either one or none of the two SNPs actually tag DEFA3 gene-containing
haplotypes, but not both. If rs2702852 does tag DEFA3 gene
presence/absence, and if it has a significant effect on CF lung disease severity,
the low p-value (0.02) would suggest an effect that is so weak as to be of no
further interest. The SNP to achieve genome-wide significance in this GWAS
gave a p-value of 3.3x10
-8
and accounted for 1 to 2% of variation in A?& ? ? ?
homozygous individuals.
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6.7. Conclusion and Discussion
The protocol of neutrophil separation and subsequent protein extraction,
adapted from Linzmeier and Ganz (Linzmeier et al., 2005), has been shown to
work well, followed by a crude separation of the defensin peptides on a small
scale SDS PAGE gel that was used for sequencing them and a clear separation
on a larger gel. Given their small size and basic nature, neutrophil defensins
can be separated from other proteins and from each other (despite a single
amino acid difference between DEFA1, 2 and 3) on an acid urea gel. This
separation of the three defensins may even allow quantification of each
separately via quantifying band intensity on the gel. The method of
quantification used in this study is ELISA, which cannot differentiate between
DEFA1, 2 and 3, and so total quantities are measured. However, this has been
a preliminary study where only the protocol has been established and needs
to be expanded to a larger scale for studying correlation between gene copy
number of DEFA1A3 and expression levels. It is crucial that the same number
of cells from each tested individual be used for protein quantification. There
are several steps where an error in cell count can be introduced, and while
error is not completely unavoidable, reproducibility of results is necessary
between samples. The first step is counting the separated neutrophils using a
haemocytometer and subsequent aliquots of 10
5
cells are made based on this
count. Counting cells manually can vary from person to person despite
adopting the same technique, and hence should be made as uniform as
possible. Second, when these aliquots are centrifuged to pellet the cells and
remove the supernatant, the quality of cell pellet should be uniform between
samples and also the removal of supernatant. After suspending the cells in
acid, they are left overnight and then vacuum-dried to get dry protein
extracts. These extracts are suspended in 1 mL of sample buffer and at this
stage samples should be mixed uniformly and thoroughly, as it has been
observed that portions of the dry pellet can tend to remain intact. For
performing ELISA, it would be ideal if these suspensions are the correct
dilution required for testing rather than having to further dilute them, which
could potentially introduce further error. In the ELISA experiment (Figure 6.8
and Figure 6.9), the range of concentrations covered by the standards is from
0.07 ʅg/ml to 10 ʅg/ml. The previously measured concentration of neutrophil
defensins is 1-5 ʅg/106 neutrophils. Thus, using extracts from 105 neutrophils
suspended in 1 mL gave the correct dilution range to be used. However, note
that the lowest value measured is about 0.13 ʅg/ml for the 7-copy sample. If
it is assumed that lower-copy samples, or indeed samples with any number of
copies, could give lower expression levels, they would fall outside the
measuring range of this experiment. Thus, either standard concentrations or
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sample dilutions may have to be adjusted further to include all samples in the
measurable range.
To investigate whether DEFA1A3 copy number affects lung disease severity in
Cystic Fibrosis, two approaches have been used. In one, CF samples have been
typed by the four-assay system for copy number and this data has been
compared with the patients disease severity measures by our collaborators.
Lung disease severity (measured as FEV1), pancreatic sufficiency and infection
by several microorganisms, all gave no significant association with DEFA1A3
copy number. In the other, as was done in investigating other GWAS, p-values
for copy number haplotype-tagging SNPs have been requested from a CF
GWAS. Given the power of this study, we can take the observation that none
of the p-values is significant as a reliable indication that there is no effect of
alpha-defensin copy number on CF severity strong enough to warrant further
investigations.
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7. DISCUSSION
7.1. Measurement of multiallelic CNVs
Chapters 3 and 4 detail the results from and the accuracy of the PRT-based
measurement system. The use of reliable calibrators, agreement between the
four assays and the observation of mendelian segregation in families are
characteristics of this study that give confidence in the copy number
measurements. Additionally, agreement with an external, independent assay
(see Section 3.2) has also been demonstrated. The combination of these
factors is not seen in any other study for DEFA1A3measurement. While this
system has worked well in the European population, its global application is
restricted either by population-specific SNPs under primers or differences in
quality of DNA samples. The latter was observed in typing Cystic Fibrosis
samples of European origin, which gave poor results when calibrated with the
eight standard samples, but better-quality results when calibrated with
HapMap CEPH samples. This could be because of either differences in how
each DNA sample was prepared, or due to a general decline in the quality of
DNA with time. The standard DNA samples used were older and had been
through numerous freeze-thaw cycles, as compared to the HapMap CEPH
samples.
When considering the general applicability of PRT for CNV measurement, it is
greatly restricted by the availability of appropriate paralogous sequences.
What other methodologies offer an advantage over these limitations? Locus-
specific studies for DEFA1A3 are limited to Aldred et al (Aldred et al., 2005)
and Linzmeier et al (Linzmeier et al., 2005) which use MAPH and real-time PCR
respectively, and have their own shortcomings as has been discussed
previously (see Section 1.2). More recent studies for copy number genotyping
are genome-wide, either genome-wide CNV arrays (array CGH) or whole-
genome sequencing using next-generation technologies. Genome-wide CNV
array study with the highest resolution (smallest probe size) is that of Conrad
et al (Conrad et al., 2010). As shown by the comparison of their results with
the PRT-based copy numbers from this study (see Section 3.2), and especially
the tight agreement between the expected and obtained log2 hybridization
ratios, the accuracy of their results for DEFA1A3 is no less than the PRT-based
system. However, they could not assign DEFA1A3 copy numbers to the tested
samples because they did not know the copy number for the reference
sample or have any calibrating samples. This study, being genome-wide, was
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meant to characterize as many CNVs as it could, and highly variable CNVs like
DEFA1A3, if they remained intractable to their approach, were not pursued
further. This is true for all genome-wide approaches. Their concern is
obtaining a global picture rather than pursuing individual loci.
So how useful or reliable can these emerging technologies be for genotyping
multiallelic CNVs? A next-generation sequencing study for measuring CNVs
using read depth by Sudmant et al (Sudmant et al., 2010) has been briefly
discussed previously (Section 1.2). Unlike the array-based studies where the
relative hybridization signal from two samples is used to infer copy number,
which makes it necessary to know the copy number of one of those samples
at any given locus, genome-wide sequencing makes use of read depth, relying
on the fact that largely the genome is only in two copies and any variation
from this can be measured and assigned copy numbers. From the whole
genome there will be instances of all copy number classes, 0 to hundreds, and
if read depth is an accurate measure, they can be assigned without any prior
knowledge of copy numbers in any sample. However, the amplification of the
short reads prior to sequencing can introduce a bias, such that the
representation of the reads may not accurately mirror their relative
abundance in the test genome. This may systematically affect some loci more
than others and could also be stochastic, such that repeated sequencing of
the same genome on different occasions may lead to different results for the
same loci (batch effect) (Taub et al., 2010). This batch effect is mainly due to
sampling variability. If we consider sampling to be a random process it should
follow the Poisson distribution. A 10x coverage of a genome in a sequencing
experiment would mean that a 7-copy repeat sequence, 10kb in size, should
on average have 7000 reads ideally, if the average read length is 100 bp. With
such high reads, the probability of assigning a copy number other than 7 is
negligibly low. However, for copy-variable regions, such small read lengths
mean that actual sequences that can be unambiguously assigned to their
position in the genome are much fewer than the entire variable sequence. In
the case of the alpha defensin locus, for example, there will be ambiguity
between the full and partial repeats, between the DEFA1/3 genes and DEFA4
gene and between other surrounding paralogous sequences or dispersed
repeats. This reduces coverage by a magnitude depending upon the CNV locus
in question. To overcome these inconsistencies, an approach using unique
molecular identifiers has been developed (Kivioja et al., 2011). The
attachment of synthetic DNA barcodes to a fragmented sample prior to its
amplification allows the counting of sequences via observation of unique
barcodes rather than read depth. It has been shown to work well for whole
chromosome copy numbers (aneuploidies, X and Y chromosomes etc.) with a
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higher accuracy than the read depth method. For whole chromosome copy
numbers, DNA equivalent to one genome was sampled as a starting material.
This dilution approach is probably not feasible for CNVs in the size range of
kilobase pairs due to sampling bias, unless the same genomic sample is tested
several times.
It remains to be seen what combination of approaches would allow accurate
CNV measurement for submicroscopic variant loci, such as DEFA1A3. More
generally, it would probably be a combination of several approaches
(genome-wide and locus specific), depending upon the locus and its
characteristics, which would allow large-scale and accurate CNV genotyping of
the level that is required for further structural and functional studies.
7.2. Evolution of DEFA1A3 Haplotypes
Using haplotype information for DEFA1A3 copy numbers inferred from
segregation in CEPH families and combining it with genotype data of
surrounding SNPs has allowed a view of haplotypic structure in Europeans.
SNPs have been found that tag copy number lineages and also other features
of the locus, e.g. presence of the DEFA3 gene or the Indel-5 minor allele.
However, only one SNP association with copy number haplotypes, that of
rs4300027, has been validated, and it is not found in non-European
populations. In the Japanese population, although only diploid copy numbers
were available for analysis, it nevertheless has shown the presence of distinct
haplotypes that allow copy number tagging by SNPs. The Chinese and African
populations do not show any strong LD between SNPs and copy number
classes of repeats. Without further knowledge on the locus, several plausible
evolutionary paths can be constructed to explain these observations.
Simultaneously, characteristics of this locus can be inferred, for example the
rate of copy number change.
In the absence of selection, limited variation in the Europeans and Japanese
shows the limit of the copy number mutation rate. For a multiallelic locus
such as DEFA1A3, recombination between haplotypes would be considered
the main mechanism giving rise to copy number changes. If recombination
changed copy numbers often enough then LD with surrounding markers
would have broken down. Of course recombination could also occur without
changing copy numbers, but still affecting linkage with surrounding markers. It
could also result in gene conversion events within the repeats, again without
affecting copy numbers. As stated in Chapter 4, not observing any copy
number change in the number of transmissions in the CEPH families studied
allows a tentative upper limit for copy number-changing rate to be estimated
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(8.86x10
-3
mutations per meiosis, 95% CI). It cannot be said how low it
actually might be.
This restricted variation in the Europeans and Japanese may have come about
due to a bottleneck effect and further genetic drift. When considering this
locus in terms of number of repeats alone, assuming no selection, and looking
at the African and Chinese populations only, the observed frequency of copy
number classes can be explained by a balance between mutations that
increase copy number and those that decrease it. This idea would be similar
to the phenomenon of equilibrium allele frequency distribution in
microsatellites, although the mechanism of copy number change would not
be the same. Given the strong bottleneck effect observed in the Europeans
and Japanese, as evidenced by their LD structure, they are excluded from this
consideration.
In the discussion so far, the possibility of selective forces acting upon this
locus has been ignored. A lot can only be hypothesized regarding selection
because it is unknown how important variation in defensin levels can be for
human health or even if expression varies significantly according to the
haplotypes a person possesses. For simplicity we assume that defensin levels
are affected by genomic variation. We must consider not only variation in
terms of number of repeats, but also in terms of sequence variants within
those repeats that might affect expression. For example, this would mean that
not all 5-copy haplotypes would give the same level of expression, but varying
levels depending upon the type of repeats making up the array. One scenario
that would explain the current common European haplotypes could be that
they were selected for by agents encountered by early Europeans on the basis
of the number of functional repeats or variants that affect expression levels.
For example, this would explain how all 5-copy haplotypes observed in CEPHs
have allele T at SNP rs4300027, whereas non-Europeans have both C and T.
The strength of the selective pressure would dictate how readily some alleles
would be lost and others become frequent. The same kind of hypothesis could
be applied to the Japanese, where high-copy haplotypes have become much
more common, and can be taken as an indication for higher defensin levels to
be beneficial in the environments faced by that population. Selection could
also explain the general copy number frequency distribution such that a
median number of defensins (6, 7 or 8) is beneficial, while lower numbers are
harmful/less beneficial under some selective forces and higher numbers are
harmful under others. However, this would not be true for the Japanese
population where the copy number frequency distribution does not follow the
normal-like distribution seen in other populations. Another possibility in the
European and/or Japanese populations is that selection might have occurred
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on another locus in the same LD region, and that is the DEFA5 gene. This
would indirectly limit variation or make certain haplotypes more common.
Another important aspect of the European haplotypes that remains
unexplored in this study is the arrangement of repeats along the array. Is the
DEFA3 gene always present in the partial repeat? Is the Indel-5 minor allele
present on repeats with a DEFA1 gene? Answers to these questions will build
a finer picture of haplotypic diversity, which in turn will help to understand
the evolution of the locus. For example, it has been observed that 5-copy
haplotypes largely carry only a single copy of the Indel-5 minor allele (28 out
of 34). So in all those haplotypes is it always the same repeat that carries the
Indel-5 minor allele or is it several different positions of repeats? If it is the
first instance, it builds a picture of lower variation than if it is the latter case.
We already know of a variant feature that splits these haplotypes into two
groups, and that is that six out of the twenty-eight have no DEFA3while the
rest have at least one copy of it. However, it does not mean that these
haplotypes must differ in terms of the Indel-5 minor allele position.
Additionally, even if they all did carry the same arrangement of repeats with
respect to the Indel-5 variant, they could still be a case of identity-by-state
rather than identity-by-descent. However, since these features seem to be
well-tagged by SNPs in the haplotypes studied, they are more likely to be
identical-by-descent.
Whatever the mechanism was that led to the restricted variation in the
Europeans, it predicts that further definition of the haplotypes in terms of
types of repeats depending upon sequence variants within them and their
position in the arrays should again show a limited number of haplotypes that
are tagged by surrounding SNPs. Ultimately, it might be possible to define a
hierarchical set of SNPs, probably beginning with rs4300027, whose
genotypes will us allow to follow much more well-defined haplotypes than
just total copy number haplotypes.
7.3. DEFA1A3 CNV and Clinical
Phenotypes
In this study, the effect of copy number variation of the alpha defensin genes
has been investigated in several immunity-related diseases via genotypes of
SNPs that tag copy number lineages, and no significant association has been
found. There was no prior indication for these defensins to affect any of the
phenotypes studied, or any not investigated. How important a role do
defensins play normally? Neutrophils store huge amounts of these peptides,
but also have other antimicrobial peptides and oxidative killing mechanisms.
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In two known conditions of neutrophil defensin deficiency, Specific Granule
Deficiency (SGD) and Chediak-Higashi Syndrome (CHS), it is not just the
defensins that are deficient but also other neutrophil granule components,
like elastase, myeloperoxidase and lactoferrin, all with antimicrobial
functions. In both diseases, patients suffer from immune deficiency and
recurrent infections. Another disease of phagocyte insufficiency is Chronic
Granulomatous Disease (CGD) which is caused by reduced or no production of
superoxide radicals in the neutrophils, monocytes and macrophages. CGD
patients are highly susceptible to infections from bacteria and fungi. This
indicates that the absence of antimicrobial mechanisms in the neutrophil
other than the defensins is sufficient to cause immune deficiency, which
diminishes the importance of defensins despite their large quantities. It would
be interesting to see if defensin gene copy number would affect disease
severity in CGD, but since it is a rare and heterogenous group of diseases
(incidence estimated at 1 in 250,000), large sized samples matched for genetic
mutation and available clinical data will be difficult to obtain.
The effect of gene copy number on protein expression also remains to be
established. If say expression was proportional to the number of functional
DEFA1A3 copies, then it would not be the total copy number, but the copy
number of functional repeats that would matter. Given that this locus is highly
variable in copy number in the normal population, it would not be surprising
to find haplotypes where only some or even none of the repeats produces a
functional copy of the peptides. Thus, when correlating gene copy numbers
obtained from PRT-based measurements with protein expression levels, if the
results reveal variation in protein levels but not in a coherent manner relative
to copy number, it might be indicative of sequence variants affecting
expression. This situation would also render rs4300027 useless as a proxy for
copy number in functional studies.
Spatial arrangement of the repeats may also be important if expression
depended upon position. In this possible scenario, expression may be
restricted to a particular repeat position, e.g. the partial repeat at the
centromeric end, or the full repeat at the telomeric end would be the only
one to be expressed. This would give each individual two transcribed copies
which may have varying levels of expression based upon sequence variants.
However, previous studies have shown not only that protein levels vary
between people (Linzmeier et al., 2005), but also that mRNA levels of DEFA1
and DEFA3 have the same ratio as does the DEFA1 and DEFA3 gene numbers
(Aldred et al., 2005). This indicates that at least most, if not all repeats are
transcriptionally active. Aldred et al also found that the level of mRNA
expression from DEFA3 genes was twice that from DEFA1 genes. It will be
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interesting to see if this replicates in terms of protein levels. ELISA will not
allow separate quantification of the three peptides, but gel band intensity on
an acid urea gel might. However, either or both of DEFA1 and DEFA3 peptides
are converted to DEFA2 which could alter their ratios.
Results from studying the correlation between gene numbers and protein
levels and defining the haplotypes at a finer level of sequence variance and
spatial arrangement will be informative for each other. While variation in the
repeat haplotypes might help explain variation in expression alongside
unravelling evolutionary history, how expression correlates with copy number
will help in understanding the functional significance and potential selective
forces (or absence of) that might have affected the evolution of this locus.
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